University of Texas at El Paso

DigitalCommons@UTEP
Open Access Theses & Dissertations

2016-01-01

Elucidating The Molecular Mechanism Of Action
By Which RS1-208b Induces Apoptosis In
Hematological Cancers
Ruben Israel Calderon
University of Texas at El Paso, ruben.israel.calderon@gmail.com

Follow this and additional works at: https://digitalcommons.utep.edu/open_etd
Part of the Biology Commons, Cell Biology Commons, and the Molecular Biology Commons
Recommended Citation
Calderon, Ruben Israel, "Elucidating The Molecular Mechanism Of Action By Which RS1-208b Induces Apoptosis In Hematological
Cancers" (2016). Open Access Theses & Dissertations. 614.
https://digitalcommons.utep.edu/open_etd/614

This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations
by an authorized administrator of DigitalCommons@UTEP. For more information, please contact lweber@utep.edu.

ELUCIDATING THE MOLECULAR MECHANISM OF ACTION BY WHICH
RS1-208b INDUCES APOPTOSIS IN HEMATOLOGICAL CANCERS

RUBEN ISRAEL CALDERON
Master’s Program in Biological Sciences

APPROVED:

Renato Aguilera, Ph.D., Chair

Giulio Francia, Ph.D.

Rachid Skouta, Ph.D.

Charles Ambler, Ph.D.
Dean of the Graduate School

Copyright ©

by
Ruben Israel Calderon
2016

Dedication

I dedicate this thesis to my parents.

ELUCIDATING THE MOLECULAR MECHANISM OF ACTION BY WHICH
RS1-208b INDUCES APOPTOSIS IN HEMATOLOGICAL CANCER

by

RUBEN ISRAEL CALDERON, B.A.

THESIS

Presented to the Faculty of the Graduate School of
The University of Texas at El Paso
in Partial Fulfillment
of the Requirements
for the Degree of

MASTER OF SCIENCE

Biological Sciences
THE UNIVERSITY OF TEXAS AT EL PASO
December 2016

Acknowledgements
I’d like to thank Dr. Renato Aguilera for guiding me through this project and my thesis
committee members Dr. Giulio Francia and Dr. Rachid Skouta for providing constructive feedback
and valuable insights throughout the process.
My deep gratitude goes to Dr. Varela, Denisse, Sarah, Lisett, and Yoshira for helping
troubleshoot procedures and helping sharpen my understanding of biology through in-depth
discussions and analyses of literature. My appreciation also extends to the Aguilera lab, the
Francia lab, and the staff at the BBRC as well as Dr. Skouta’s lab members Madan and Carlos who
conducted the in silico docking of RS1-208b.

v

Abstract
The 26S proteasome has been successfully targeted to treat multiple myeloma. However,
the effect can sometimes be reversed as cells acquire resistance to chemotherapy. Recently,
combining proteasome inhibitors with indirect proteasome inhibitors has been proposed in order
to delay and even reverse resistance. Small molecules derived from 4-piperidinone that maintain
an unsaturated β-carbonyl group are thought to interact with the thiol group of catalytically active
cysteine residues in deubiquitinases that associate with the 26S proteasome, effectively inhibiting
the proteasome.
RS1-208b was selected following a high-throughput screening of a small library of 4piperidinone derived curcumin structural analogs due to its selectivity towards hematological
cancers and its ability to inhibit inflammatory cytokine production. In silico docking experiments
showed RS1-208b can inhibit cysteine deubiquitinases by bringing the unsaturated β-carbonyl in
close proximity to the thiol group. AmpliSeq analysis revealed RS1-208b elicits a cellular response
that is similar to that of proteasome inhibitors collected in the Connectivity Map. Treatment with
RS1-208b leads to the rapid accumulation of poly-ubiquitinated proteins, which initiates a cellular
response that culminates in cell death. RS1-208b up-regulated transcripts in the PERK-mediated
unfolded protein response and the intrinsic pathway of apoptosis, which was verified using several
fluorescence based assays. In vivo, RS1-208b delayed the tumor growth in RAMOS xenograft
models and increased event-free survival time.

vi

Table of Contents
Acknowledgements ..........................................................................................................................v
Abstract .......................................................................................................................................... vi
Table of Contents .......................................................................................................................... vii
List of Tables ................................................................................................................................. ix
List of Figures ..................................................................................................................................x
List of Illustrations ......................................................................................................................... xi
1. Introduction ..................................................................................................................................1
1.1 Cancer World Wide ..........................................................................................................1
1.2 Childhood Cancer World Wide and in the U.S.................................................................1
1.3 Hispanics in the U.S. and Childhood Cancer ....................................................................3
1.4 Standard of Care for Childhood Cancers ..........................................................................3
1.5 Curcumin Promises ...........................................................................................................4
1.6 Curcumin Limitations .......................................................................................................6
1.7 Structural Analogs of Curcumin .......................................................................................7
1.8 Research Rationale............................................................................................................8
2. High-Throughput Screening of a Library of Compounds on a Panel of Cancer Cell Lines ........9
2.1 Initial Screening of Library of Compounds on Jurkat and Nalm-6 ..................................9
2.2 RS1-208b Against a Panel of Hematological Cancer Cell Lines ...................................11
2.3 RS1-208b Against a Panel of Adherent Cancerous Cell Lines .......................................13
3. Evaluating Activity of RS1-208b on Hematological Cancers ...................................................15
3.1 Assessment of Cytotoxicity Induced by RS1-208b ........................................................15
3.2 Assessment of the Effect RS1-208b Has on the Cell Cycle ...........................................18
4. Evaluating Apoptosis Induced by R1-208b ...............................................................................23
4.1 Assessment of Phosphatidylserine Externalization Induced by RS1-208b ....................23
4.2 Assessment of Mitochondrial Involvement in Apoptosis Induced by RS1-208b ...........26
4.3 Assessment of the Involvement of Caspase 3 in RS1-208b Induced Apoptosis ............30
4.4 Assessment of the Involvement of Caspase 8 in RS1-208b Induced Apoptosis ............33
4.5 Assessment of Tumor Necrosis Factor α (TNFα) Production ........................................34
vii

5. Identifying the Molecular Pathway of RS1-208b Induced Apoptosis .......................................38
5.1 Transcriptome Analysis Using AmpliSeq ......................................................................38
5.2 AmpliSeq Data Mapping onto Gene Ontology...............................................................42
5.3 PERK-Mediated Unfolded Protein Response and Intrinsic Apoptosis...........................45
6. Identifying the Molecular Target of RS1-208b .........................................................................54
6.1 Connectivity Map Analysis.............................................................................................54
6.2 RS1-208b Inhibits the Proteasome Indirectly .................................................................57
7. Confirming Up-Regulation of Transcripts Using RT-qPCR .....................................................66
7.1 PMAIP1 Up-Regulation..................................................................................................66
8. Evaluating Proteotoxic Stress and Noxa Translation Induced by RS1-208b ............................70
8.1 Accumulation of Poly-Ubiquitinated Proteins in Response to RS1-208b ......................70
8.2 Noxa Expression in Response to RS1-208b ...................................................................73
9. Evaluating RS1-208b in Vivo.....................................................................................................77
9.1 Severe Compromised Immuno-Deficient (SCID) Mice and Cell Line Selection for
in Vivo Studies .............................................................................................................77
9.2 Pilot Experiment-RAMOS Subcutaneous Model ...........................................................78
9.3 Development of Intraperitoneal Model of RAMOS .......................................................79
9.4 PEG-400 Selection for the Vehicle .................................................................................81
9.5 RAMOS Subcutaneous Model ........................................................................................83
9.6 RAMOS Intraperitoneal Model ......................................................................................86
10. Conclusion ...............................................................................................................................88
10.1 Discussion .....................................................................................................................88
10.2 Future directions ...........................................................................................................90
References ......................................................................................................................................92
Glossary .......................................................................................................................................101
Vita ............................................................................................................................................104

viii

List of Tables
Table 1. IC50 Values Following 24 Hours of Treatment Obtained by MTS ................................. 11
Table 2. RS1-208b IC50 Values of a Panel of Cell Lines Following 24 Hours of Treatment....... 12
Table 3. RS1-208b IC50 Values on a Panel of Adherent Cell Lines Following 72 Hours of
Treatment ...................................................................................................................................... 13
Table 4. RNA Extraction Results for AmpliSeq Analysis Indicate High Purity RNA................. 39
Table 5. List of Genes That Were More Than 5-fold Up-Regulated in Response to Treatment
with RS1-208b for 6 Hours Compared to Vehicle Control .......................................................... 40
Table 6. List of Genes That Were More Than 5-Fold Down-Regulated in Response to Treatment
with RS1-208b for 6 Hours Compared to Vehicle Control .......................................................... 41
Table 7. GO Pathways with the Most Number of Genes Significantly Affected by Treatment
with RS1-208b .............................................................................................................................. 44
Table 8. PERK-Mediated Unfolded Protein Response (GO:0036499) ........................................ 45
Table 9. Intrinsic Apoptotic Signaling Pathway in Response to Endoplasmic Reticulum Stress
(GO:0070059) ............................................................................................................................... 52
Table 10. Molecular Signature of RS1-208b Compared to Perturbagens in cMAP ..................... 55
Table 11. Docking Scores of RS1-208b and b-AP15 to UCHL5 ................................................. 63
Table 12. Docking Scores of RS1-208b and b-AP15 to USP14 ................................................... 65
Table 13. RNA Extraction for RT-qPCR Shows High Purity ...................................................... 66
Table 14. Primer Sequences Used in RT-qPCR Experiments ...................................................... 67
Table 15. Real-Time PCR Protocol .............................................................................................. 68
Table 16. Comparison of Up-Regulation Fold-Count (FC) between AmpliSeq and RT-qPCR .. 68
Table 17. Tumor Size after 28 Days ............................................................................................. 78
Table 18. Ratio of Tumor Growth Comparing RS1-208b Treated Mice with Vehicle Treated
Mice in Subcutaneous Model of RAMOS .................................................................................... 84

ix

List of Figures
Figure 1. Library of Curcumin Analogs ....................................................................................... 10
Figure 2. RS1-208b Induces Cell Death in Hematological Cancer Cells ..................................... 16
Figure 3. RS1-208b Does Not Induce Cell Cycle Arrest .............................................................. 21
Figure 4. RS1-208b Induces Phosphatidylserine Externalization................................................. 25
Figure 5. RS1-208b Induces Mitochondrial Depolarization ......................................................... 28
Figure 6. RS1-208b Induces Caspase 3 Activation ...................................................................... 32
Figure 7. RS1-208b Does Not Induce the Activation of Caspase 8 .............................................. 34
Figure 8. RS1-208b Does Not Lead to the Production and Release of TNFα .............................. 36
Figure 9. Number of Genes Differentially Regulated Listed by GO Term .................................. 43
Figure 10. Molecular Structures of RS1-208b and b-AP15 .......................................................... 59
Figure 11. In Silico Docking of RS1-208b onto UCHL5 ............................................................ 61
Figure 12. In Silico Docking of RS1-208b onto USP14 ............................................................... 64
Figure 13. Accumulation of Poly-Ubiquitinated Proteins after 1 Hour of Treatment with RS1208b............................................................................................................................................... 72
Figure 14. Noxa Up-Regulation after 5 Hours of Treatment with RS1-208b .............................. 74
Figure 15. Pilot Experiment of Subcutaneous Model of RAMOS ............................................... 79
Figure 16. Weight Trends of Mice Injected Intraperitoneally with RAMOS ............................... 80
Figure 17. Assessment of Cell Death Induced by Vehicles PEG-400 and DMSO ...................... 83
Figure 18. RS1-208b Delays Tumor Growth in RAMOS Subcutaneous Model .......................... 84
Figure 19. RS1-208b Extends Event-Free Survival Time in RAMOS Subcutaneous Model ...... 85
Figure 20. RS1-208b Extends Event-Free Survival Time in the RAMOS Intraperitoneal Model 86

x

List of Illustrations
Illustration 1. Activated PERK Phosphorylates eIF2α ................................................................. 50
Illustration 2. ATF4/3 Up-Regulate PMAIP1 ............................................................................... 51
Illustration 3. Phosphatidylserine Externalization and Caspase 3 Activation Following
Mitochondrial Depolarization ....................................................................................................... 52

xi

1. Introduction
1.1 Cancer World Wide
Cancer refers to a group of diseases characterized by the dysregulation of pathways that
control proliferation and subsequent invasion of abnormal cells, which can lead to death. Cancer
is responsible for more deaths worldwide than AIDS, tuberculosis, and malaria combined,
accounting for an estimated 8.2 million deaths in 20121. The death estimate is expected to reach
13 million by the year 20301. Moreover, the majority of the expected new cases (rising to 21.7
million world-wide by 2030) will occur in developing countries1, where access to adequate
medical care is limited, further driving health outcome disparities.

1.2 Childhood Cancer World Wide and in the U.S.
World-wide, leukemia and lymphoma account for the majority of childhood cancer
cases1. Cancer in children and adolescents is rare, though it is one of the leading causes of death
in children in developed countries1, where incidence rates are higher than in developing
countries2. However, mortality rates in developed countries are substantially lower than in
developing countries2, presumably due to access to medical care.
Leukemia is the most common childhood cancer world-wide, and accounts for about one
third of all childhood cancer, with acute lymphoblastic leukemia (ALL) accounting for, roughly,
83% of all pediatric leukemia cases1,3. Non-Hodgkin’s Lymphoma (NHL) is the third most
common childhood cancer across all demographics in the U.S., though in the continent of Africa,
it is the most common childhood cancer in the form of Burkitt’s Lymphoma (BL)1.
Developing countries do not generally invest resources into childhood cancer treatment1
since other public health concerns, such as combating infectious diseases, are prioritized. In these
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countries, as the number of deaths due to preventable diseases decreases, childhood cancers will
emerge as one of the leading causes of death1. Furthermore, health outcomes appear to be more
successful when treatment is managed by a children oncology specialist at a children’s cancer
center1, suggesting an important role for medical infrastructure in determining availability of
effective treatment and, ultimately, patient outcomes.
However, even in the U.S., outcome disparities between socio-economic and ethnic
groups is observed3,4, highlighting a need to improve the medical infrastructure world-wide to
increase access to adequate medical care. In addition, it is important to note that even when
access to chemotherapy is controlled in clinical trials, health disparities (between Hispanic and
non-Hispanic White children in the U.S.) are readily observed3, suggesting access to treatment
will not be sufficient to improve outcomes around the world. Investment in basic research and
clinical trials to target those populations who are not well served by the current standard of care
for these childhood cancers. In Texas, the East and West parts of the state are roughly equally
distributed (covering 50.9% and 49.1%, respectively), with East Texas containing 88.8% of the
population and West Texas containing 11.2%4 and childhood cancer incidences reflect the
population distribution, with East Texas seeing 90.9% of pediatric cancer patients compared to
9.1% in West Texas4. Yet West Texas experiences 14.6% pediatric cancer patient mortality,
roughly 1.5 times the mortality rate observed in East Texas4. And the difference in outcomes can
be partially attributed to the disparities in number of pediatric oncologist (4.2% available in West
Texas), the number of NCI-designated cancer centers (0 in West Texas, 4 in East Texas), and
total grant funding (NCI, DOD, CPRIT) per person: $3.40 in West Texas compared to $35.50 in
East Texas4.
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1.3 Hispanics in the U.S. and Childhood Cancer
The Hispanic population is the fastest growing demographic in the United States,
growing by 43% between 2000 and 2010, four times the growth rate of the total population3.
However, the distribution of the Hispanic population in the U.S. is not homogenously
distributed, concentrated in the south western part of the country, along the U.S.-Mexico border.
Among the general U.S. Hispanic population, cancer is the leading cause of death3, having
surpassed cardiovascular disease.
Hispanic children developing cancer in 2012 accounted for 2% of the new cases of cancer
in the U.S. Hispanic population, compared to childhood cancers accounting for <1% of the total
new cancer cases in the U.S. population3. Though this discrepancy might be accounted for by the
difference in age demographics between the Hispanic and total U.S. population, Hispanic
children have the highest incidence rates of ALL of any demographic in the U.S3. In addition,
Hispanic children with ALL have higher mortality rates compared to non-Hispanic White
children and African American children3, and despite the similarity in the incidence rates for
lymphoma between Hispanic children and non-Hispanic White children, survival rates for
Hispanic children are markedly lower3.

1.4 Standard of Care for Childhood Cancers
The past 30 years have witnessed many advances in cancer treatment and early detection
which have combined to greatly improve health outcomes, as measured by the increase in 5 year
survival rates1,3. However, for Hispanic children in the U.S., 5-year survival rates are
statistically significantly below those of non-Hispanic White children for all childhood cancers
combined3. One of the most dramatic differences in both incidence and survival rates between
Hispanic and non-Hispanic children is observed in ALL. A possible explanation for this disparity
3

in both incidence rates and outcomes could be attributed to socio-economical differences that
impede or restrict access to appropriate screening and medical treatment1,4. In Texas, for
example, there are 4 NCI-designated cancer centers, but they are all concentrated in East Texas4.
In order for a West Texas child to receive the same medical treatment as a child from East Texas,
s/he would have to travel, possibly as much as 746 miles (from El Paso, TX to Houston, TX).
Although improving access to adequate medical care has been correlated with improved survival
rates world-wide1, differences in survival rates between Hispanic and non-Hispanic white
children are also apparent in some clinical trials where all patients receive equal treatment,
suggesting the observed disparity in survival rates is also, partially, due to a disproportional
number of high risk leukemia cases developing in Hispanic children3 and that the currently
accepted standard of care for these patients are simply not as effective.
Current treatment options approved by the U.S. Food and Drug Administration for both
childhood leukemia and Non-Hodgkin’s lymphoma may lead to acute and long term, unwanted
side effects5. Chemotherapeutic regiments for leukemia and non-Hodgkin’s lymphoma typically
include the topoisomerase II inhibitor Doxorubicin, which has been shown to be effective against
most hematological malignancies6; however, its use has been associated with myocardial tissue
damage, which can lead to fatal congestive heart failure7.
Considering the age distribution of the Hispanic population in the U.S., and the continued
expected growth, safer, more effective treatments need to be developed in order to fight
childhood cancer along the U.S.-Mexico border.

1.5 Curcumin Promises
Curcumin [1,7-bis(4 hydroxy-3-methoxyphenyl)-1E,6E-heptadiene-3,5-dione] is the most
abundant curcuminoid derived from the rhizomes of the south Asian plant Curcuma longa8. It
4

has been used in Chinese and Indian traditional medicine for many centuries to treat a variety of
illnesses and ailments including infections, burns, and certain diseases8,9. Curcumin has been
described as having antioxidant, anti-microbial, anti-inflammatory, and anti-cancer properties.
Research into curcumin over the past few decades has revealed it to be a pleiotropic molecule,
capable of modulating a broad range of cell signaling pathways8,10–13.
Many molecular targets of curcumin in a variety of cancer cell lines have been proposed
and studied over the years. In vitro, curcumin has shown the potential to influence a wide range of
cell signaling pathways through its antioxidant12, anti-inflammatory14, antiproliferative and
proapoptotic properties15, most notably the modulation of the p53 pathway, NF-kB pathway,
MAPK pathway, Akt pathway, as well as JAK/STAT pathway 8,11,13,16.
In vitro, curcumin has been shown to selectively induce apoptosis in cancer cell, whereas
non-cancerous cells treated with similar concentrations of curcumin remain unaffected9,17.
Furthermore, in vivo studies using curcumin to treat mouse models bearing cancer have indicated
curcumin is very well tolerated and does not induce the toxic effects normally associated with
conventional chemotherapy18. There have been several clinical trials assessing the tolerance and
efficacy of curcumin using doses as high as 12g per day with only mild side effects19–21. Curcumin
has been shown to display protective effects, especially of the liver and kidney tissue22,23, of organs
heavily involved in chemotherapy metabolism and generally affected by harsh treatments. The
selectivity, safety of consumption, and systemic protective effects make curcumin a viable
candidate for chemotherapy option either as stand-alone therapy or as part of a chemotherapeutic
regiment. However, despite its many promises, curcumin is not an approved treatment for cancer10
and remains a poor option for chemotherapy, in large part owing to its bioavailability19.

5

1.6 Curcumin Limitations
Turmeric has been a staple ingredient in Indian cuisine for many centuries, and thus, has
been consumed on a regular basis by people in South Asia. In the clinical setting, no detrimental
effects were reported in a dose escalating study where subjects consumed up to 12g of curcumin
per day, with effective doses reported between 100mg-6g per day (reviewed in19–21).
Despite the low systemic toxicity14,24 and encouraging in vitro results against a wide
variety of cancers12,15,17, bioavailability remains the biggest challenge to using curcumin as an
effective alternative to current chemotherapy treatment options. Curcumin’s poor absorption,
rapid metabolism, and the rate at which it is systematically eliminated all contribute to its limited
bioavailability19.
Consistently low serum, plasma, and tissue concentrations of curcumin have been
observed despite high doses of curcumin administered, with peak levels being reached by 1 hour,
followed by rapid systemic clearance (reviewed in 19,20,25). Oral delivery of curcumin has shown
the lowest plasma concentrations. However, intraperitoneal or intravenous delivery only appears
to marginally improve plasma concentrations19.
There have been several approaches taken to increase curcumin’s efficacy in vivo and
improve its bioavailability19. The most frequently reported are delivery methods using either
nanoparticles20,25–27, liposomes, or phospholipid complexes and the synthesis of structural
analogs28–31. Improving the delivery method through novel formulations using nanoparticles or
liposomes could improve the permeability of curcumin and protect it from being metabolized
into inactive metabolites, thereby increasing bioavailability. However, structural analogs of
curcumin synthesized from 4-piperidinone have been previously reported to exert stronger
cytotoxic effects in vitro and in vivo compared to curcumin, improved solubility, and are being
evaluated in clinical trials for improved bioavailability and efficacy28–35.
6

1.7 Structural Analogs of Curcumin
Curcumin’s chemical structure is an important aspect in its ability to regulate and target a
large variety of molecules32. The synthesis of structural analogs of curcumin has provided
compounds with improved cytotoxic profiles and bioavailability28–31,36,37. Analysis of structureactivity relationships of curcumin analogs has identified the α,β-unsaturated ketone moiety as the
most important property that confers cytotoxicity to these structural analogs32.
The modulation of pathways exerted by curcumin that lead to cell death are thought to
occur through molecular interactions involving its α,β-unsaturated di-ketone moiety32. Conjugated
enones can act as Michael acceptors in a Michael reaction38, allowing a strong nucleophile to attack
the β-carbon. Thiols appear to be the preferred nucleophiles for a Michael reaction involving the
α,β-unsaturated di-ketone moiety of curcumin, with early research focusing on curcumin’s ability
to induce cell death by inhibiting glutathione32.
The hepta-carbon backbone of curcumin is shortened in mono-ketone structural analogs of
curcumin that have been synthesized from 4-piperidinone, and the α,β-unsaturated di-ketone
moiety of curcumin has been reduced to an α,β-unsaturated ketone moiety. Curcumin is a highly
hydrophobic compound with poor water solubility that exhibits pH dependent keto-enol
taumerism, being found predominantly in the keto form at neutral and acidic conditions, and in its
enol form in alkaline conditions11. The 4-piperidinone synthesized structural analogs of curcumin
have a nitrogen atom on the ring which contains the ketone, which, along with generally more
numerous or stronger election withdrawing groups on the aromatic rings, increases the stability of
the compound, shifting the keto-enol taumerism balance towards the keto side, and, thus, helping
stabilize the α,β-unsaturated moiety and increasing the β-carbon’s reactivity. Evaluation of these
structural analogs has consistently shown increased cytotoxicity profiles compared to curcumin,
7

as well as improved solubility29,30,37, suggesting the structural analogs have the potential to be
better therapeutic options.

1.8 Research Rationale
Though survival rates for the most common childhood cancers have steadily increased
across all demographics over the past few decades1,3, the discrepancy in survival rates between
Hispanic and non-Hispanic white children highlights the need for developing novel chemotherapy
options for the high-risk cases of Hispanic children. Structural analogs of curcumin previously
characterized in our laboratory indicated that these compounds have improved cytotoxicity profiles
(compared to curcumin) and appear to selectively affect leukemia and lymphoma in vitro28.
Despite clinical trials being out of the scope of this thesis project, we do hope to draw attention to
the potential benefits of utilizing structural analogs of curcumin against hematological cancers by
elucidating the molecular mechanism of action by which they induce programmed cell death.

8

2. High-Throughput Screening of a Library of Compounds on a Panel of
Cancer Cell Lines
2.1 Initial Screening of Library of Compounds on Jurkat and Nalm-6
Initial screening of the library of curcumin analogs (Figure 1.) was performed by MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt) on two leukemia cell lines: Jurkat (T-cell ALL) and Nalm-6 (pre-B cell ALL). Cells
were seeded at 10,000 cells/100µL/well in a 96-well plate and treated with 5-fold dilutions of the
compounds (1µM, 0.2µM, 0.04µM) for 24 hours (biological replicates = 3). The MTS was added
(20µL/well) at 20 hours and incubated for 4 hours. The plate was read using a
spectrophotometer, subtracting the absorbance of 650nm wavelength from the 490nm
wavelength, using complete media with MTS as the blank. Positive and negative controls
(hydrogen peroxide treated and untreated wells, respectively) were included in a 96-well plate;
the results were normalized to vehicle (DMSO) treated absorbance values in order to assess cell
viability after 24-hour treatment. The results (normalized to the vehicle control, DMSO) of the
assay are summarized in Table 1. IC50 values for the library of compounds over 1µM were
extrapolated from available data. For reference, Curcumin and EF-24 IC50 values are included in
the table. The concentrations tested for the reference compounds were 25µM, 12.5µM, and
6.25µM for Curcumin, and 1µM, 0.2µM, and 0.04µM for EF-24. EF-24, a structural analog of
curcumin synthesized from 4-piperidinone, has shown great efficacy in treating cancer both in
vitro and in vivo32–34,39.
The MTS assay, which is a colorimetric assay, makes use of a tetrazolium compound
that, in the presence of phenazine methosulfate (PMS), is reduced to form a soluble, colored
formazan product in biologically active cells40. Though it is unclear whether the reduction is
accomplished by NADPH or NADH41, the formation of the formazan product and appreciable
9

color change in the media measures the metabolic activity and the reduction potential of
mitochondrial dehydrogenases maintained by viable cells.

Figure 1. Library of Curcumin Analogs
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Table 1. IC50 Values Following 24 Hours of Treatment Obtained by MTS
Compound
RS-311
RS-347
RS-469
RS1-208b
RS-339
RS-479
RS-401
RS-403
RS-411
RS-447
RS-570
RS-591
RS-439
RS-579
RS-501
RS-503
EF-24
Curcumin

Jurkat IC50 (µM)
0.69 ± 0.07
0.17 ± 0.01
0.19 ± 0.02
0.17 ± 0.01
0.94 ± 0.10
0.66 ± 0.16
0.52 ± 0.31
1.57 ± 0.15
0.83 ± 0.26
0.75 ± 0.08
0.41 ± 0.20
0.77 ± 0.02
6.05 ± 6.06
0.78 ± 0.01
0.61 ± 0.19
5.84 ± 0.01
0.69 ± 0.07
10.47 ± 2.76

Nalm-6 IC50 (µM)
0.62 ± 0.05
0.18 ± 0.04
0.19 ± 0.03
0.18 ± 0.07
1.26 ± 0.44
0.39 ± 0.06
0.15 ± 0.03
2.17 ± 1.21
0.79 ± 0.12
0.73 ± 0.02
0.29 ± 0.04
0.66 ± 0.04
29.25 ± 26.22
0.64 ± 0.04
0.16 ± 0.02
6.47 ± 0.56
0.78 ± 0.02
14.12 ± 6.03

RS-347, RS-469, and RS1-208b we found to be the most biologically active compounds
of the library tested, with IC50 values of 0.17 ± 0.01, 0.19 ± 0.02, and 0.17 ± 0.01, respectively;
though it is important to note that the majority of the functional group modifications made to the
aromatic rings yielded IC50 values below 1µM in the initial screening. With one exception in the
Nalm-6 cell line, the IC50 values of the library of compounds were significantly lower than
Curcumin’s (p < 0.05). Furthermore, the majority of the compounds screened on these two cell
lines had standard deviations of the IC50 values that overlapped the IC50 of the reference drug,
EF-24, indicating that in Jurkat and Nalm-6 cell lines, they were equally as effective

2.2 RS1-208b Against a Panel of Hematological Cancer Cell Lines
RS1-208b was selected from the library of compounds tested, and 1.5g was synthesized
to provide enough compound to perform additional in vitro and in vivo assays, due to its low IC50
11

values on both Jurkat and Nalm-6 cell lines, but also because the structure (synthesized and
tested independently) has shown inhibition against IL-6 production29 and thought to be an antiinflammatory agent that could be used in combination therapy. Moreover, the compound was
shown to protect mice from LPS-induced septic death29. The compound was then re-evaluated
through MTS on a panel of hematological cancer cell lines, as well as two non-cancerous cell
lines and PBMCs (see Table 2.). Cell density was adjusted to 200,000 cells/mL due to the
minimum number of cells needed to extract sufficient RNA for sequencing, and maintained
constant throughout the remaining in vitro experiments, unless explicitly stated otherwise. Five
5-fold dilutions (25µM, 5µM, 1µM, 0.2µM, 0.04µM) of RS1-208b were tested on the panel of
cell lines. The IC50 values (normalized to DMSO) following 24 hours of treatment are
summarized in Table 2. Burkitt’s lymphoma (BJAB and RAMOS) was the disease most sensitive
to RS1-208b, followed by ALL (CCRF-CEM, Jurkat, and Nalm-6), and AML (HL-60). Hs27,
MCF-10A, and PBMCs were used as non-cancerous control cell lines.

Cell Line

Table 2. RS1-208b IC50 Values of a Panel of Cell Lines Following 24 Hours of Treatment
SI
Cell Type
Disease
IC50 (µM)
Age
Ethnicity

BJAB
CCRF-CEM
HL-60
Hs27
Jurkat
MCF10-A
Nalm-6
PBMC
RAMOS

B Lymphocyte
T Lymphoblast
Promyoblast
Fibroblast
T Lymphocyte
Epithelial
pre-B cell
PBMC
B Lymphocyte

Burkitt's Lymphoma
Acute Lymphoblastic Leukemia
Acute Myelocytic Leukemia
None
Acute Lymphocytic Leukemia
Fibrocystic Disease
Acute Lymphoblastic Leukemia
None
Burkitt's Lymphoma

0.29 ± 0.02
0.33 ± 0.01
0.52 ± 0.06
6.24 ± 0.99
0.27 ± 0.03
8.76 ± 1.14
0.36 ± 0.02
0.71 ± 0.11
0.23 ± 0.01

18.07
15.88
10.08
19.41
14.56
22.78

5
4
36
Newborn
14
36
19
3

African
Caucasian
Caucasian
Black
Caucasian
Caucasian

The selectivity index reported in Table 2. was calculated as SI = (Average IC50 of noncancerous lines)/(IC50 value of the cell line)28. Selectivity index values above 1 indicate that a
compound selectively inhibits half of the cells of a particular cancer cell lines at a concentration
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Sex
F
F
F
M
M
F
M
M

that is lower than the concentration which inhibits half of the cells of non-cancerous cell lines.
This provided a rationale for moving forward with RS1-208b to assays aimed at identifying its
molecular mechanism of action and in vivo studies since, at most biologically achievable plasma
concentrations (based on available curcumin data19), the compound is more likely to affect
rapidly dividing cancer cells but not the majority of somatic cells.

2.3 RS1-208b Against a Panel of Adherent Cancerous Cell Lines
RS1-208b was also evaluated against a panel of adherent cancer cell lines (breast cancer
cell lines: EMT-6, HCC-1419, MCF-7, MDA-MB-231, MDA-MB-231-LM2, MDA-MB-468,
T47-D; colorectal cancer cell line: COLO-205; non-cancerous cell lines: Hs27, MCF-10A),
though at the concentrations evaluated (up to 25µM) the majority of the cell lines did not reach
an IC50 value after 24 hours of treatment. Therefore, the time point for evaluation of IC50 values
through MTS for this panel of cell lines was extended to 72 hours. The results are summarized in
Table 3 (normalized to DMSO).

Table 3. RS1-208b IC50 Values on a Panel of Adherent Cell Lines Following 72 Hours of
Treatment
Cell Line
Hs27
COLO-205
EMT-6
HCC-1419
MCF-7
MCF-10A
MDA-MB-231
MDA-MB-231-LM2
MDA-MB-468
T47-D
¥standard

Disease
None
Colorectal Cancer
Breast Cancer
Breast Cancer
Breast Cancer
Fibrocystic Disease
Breast Cancer
Breast Cancer
Breast Cancer
Breast Cancer

deviations not available
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Selectivity Index
IC50 (µM)
0.59 ± 0.01
1.42
0.50 ± 0.26
1.27
0.56±0.02
0.78
0.91¥
1.22
0.58 ± 0.03
0.83 ± 0.02
1.51
0.47 ± 0.13
1.48
0.48 ± 0.04
2.15
0.33 ± 0.1
¥
0.82
0.87

Though the majority of the breast cancer cell lines and the one colorectal cancer cell line
tested had selective indices above 1, the selectivity was not as pronounced as with the leukemia
and lymphoma cell lines. Taken together, the data indicates that RS1-208b is selective against
cancer cell lines, but more precisely, it displays stronger selection and sensitivity (low IC50
values) against leukemia and lymphoma cancer cells.
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3. Evaluating Activity of RS1-208b on Hematological Cancers
3.1 Assessment of Cytotoxicity Induced by RS1-208b
The MTS is an assay that has been optimized for high-throughput screening, as it is able
to quickly evaluate whether or not compounds in question have an effect on cells. However, the
results obtained are relative to the vehicle control and the assay itself only detects a colorimetric
difference that is produces by the reduction of the tetrazolium compound. Because of this, the
MTS assay is not able to differentiate between compounds that cause cell cycle arrest and
cytotoxic compounds that induce cell death.
Therefore, to verify that treatment of cells with the compound resulted in cell death, we
investigated the cytotoxicity induced by RS1-208b on select, hematological cancer cell lines
CCRF-CEM, HL-60, Jurkat, and RAMOS. RAMOS was the most sensitive cell line to RS1-208b
in the panel and we had successfully grown a subcutaneous xenograft tumor in a mouse model.
Jurkat and CCRF-CEM were selected due to the low IC50 values, and to provide experimental
data that RS1-208b could also be used against ALL, the most common childhood cancer. The
AML cell line HL-60 was evaluated because it is one of the original cell lines in the panel from
which the Broad Institute developed the Connectivity Map42, a resource that helps elucidate the
mechanism of action of any particular compound by comparing its molecular signature against
those collected from well-known anti-cancer compounds.
Cytotoxicity was detected with the Propidium Iodide Exclusion Assay, which makes use
of a fluorescent dye that intercalates double stranded nucleic acids of dead or dying cells.
Propidium Iodide (PI), intercalates DNA and double stranded RNA segments, with little
sequence preference, at every 4-5 base pairs43. The dye is impermeable to viable cells with intact
membranes; however, upon death, the membrane becomes permeabilized and PI is able to
intercalate previously inaccessible double stranded nucleotides43.
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For this assay, 200,000 cells/mL/well were incubated in a 24-well plate (biological
replicates = 3) and treated with 0.5µM, 1µM, and 2µM of RS1-208b for 24 hours. Also included
in the plate were hydrogen peroxide treatments (positive control), untreated cells (negative
control, and vehicle treated cells (for this assay, PEG-400 was used as the vehicle). Following
incubation, 500µL of each well were removed from the plate and placed into a 5mL culture tube
along with 5µL of PI dye. The tubes were incubated in the dark at room temperature for 5
minutes then analyzed via flow cytometry using a 488nm43 OPSL Sapphire laser to excite the
fluorescent dye. The emission wavelength of PI was detected through the FL2 channel. We
interpret the percentage of the cell population fluorescing red as having compromised cell
membranes, and therefore, equivalent to percentage of cell death. Below are graphical
representations of the data acquired for the Propidium Iodide Exclusion Assay.

a)

CCRF-CEM (24 hours)
100
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% cell death
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*
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0
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(2µM)

RS1-208b
(1µM)

RS1-208b
(0.5µM)

Hydrogen
Peroxide

Figure 2. RS1-208b Induces Cell Death in Hematological Cancer Cells
a) Average values (± standard deviation) of percentage of CCRF-CEM cells stained with PI are summarized above.
Three different concentrations (doubling dilutions) were tested (p < 0.05). Cytotoxicity in response to RS1-208b was
concentration dependent in the CCRF-CEM cell line.
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b) Average values (± standard deviation) of percentage of HL-60 cells stained with PI are summarized above. Three
different concentrations (doubling dilutions) were tested (p < 0.05). Cytotoxicity in response to RS1-208b was
concentration dependent in the HL-60 cell line.
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c) Average values (± standard deviation) of percentage of Jurkat cells stained with PI are summarized above. Three
different concentrations (doubling dilutions) were tested (p < 0.05). Cytotoxicity in response to RS1-208b was
concentration dependent in the Jurkat cell line.
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d)

RAMOS (24 hours)
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d) Average values (± standard deviation) of percentage of Jurkat cells stained with PI are summarized above. Three
different concentrations (doubling dilutions) were tested (p < 0.05). Cytotoxicity in response to RS1-208b was
concentration dependent in the RAMOS cell line.

Cytotoxicity induced by RS1-208b was observed across all the cell lines and
concentrations tested (p < 0.05). Unlike the MTS assay, the PI assay does not normalize the
results to the vehicle control. Furthermore, the PI assay interrogates individual cells in the
population to assess the percentage of cells that have undergone RS1-208b induced cell death, as
opposed to comparing the reduction potential of a population of cells. However, the results
confirmed the concentration dependent effect observed by MTS (data not shown) and pointed to
cytotoxicity as the main effect induced by RS1-208b in hematological cancers.

3.2 Assessment of the Effect RS1-208b Has on the Cell Cycle
Due to the slight disagreement between IC50 values obtained through MTS and the
calculated concentration needed to induce cytotoxicity in half of the population of cells, we used
the cell cycle assay to determine whether, apart from inducing cell death, RS1-208b caused cell
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cycle arrest. An arrest in the cell cycle could reconcile the difference in concentration needed to
inhibit half the cell population and that needed to kill half the population. Moreover, with this
assay, if RS1-208b caused cell cycle arrest, it would be possible to narrow down molecular
targets by focusing our attention on the events required to pass the checkpoint of the phase in the
cell cycle at which the cell is halted.
An arrest in cell cycle is generally observed as a result of DNA damage44, where the cell
experiencing the damage initiates a cascade of events in an attempt to repair the damage (though
compounds can have an effect on other intracellular targets that will result in cell cycle arrest).
When the damage is irreversible, the cell can initiate programmed cell death through apoptosis.
The cell cycle assay determines the percentage of cells in an asynchronous population
found at each stage of the cell cycle based on DNA content. As a cell progresses through the cell
cycle, its DNA content increases accordingly. A daughter cell begins to increase its DNA content
in the synthesis phase of the cell cycle so that by the time the cell reaches the G2 phase, there is
double the amount of DNA inside the membrane of the cell than there was at the G1 phase. One
of the hallmarks of apoptosis is DNA fragmentation and the formation of apoptotic bodies44,45,
membrane bound remnants of a complete cell that encapsulate fragments of the cellular contents
of the original cell. Therefore, the cell cycle assay provides experimental data about which
phase of the cell cycle a particular compound interferes with, while also providing some
evidence of whether RS1-208b induces cell death through apoptosis.
For this assay, we opted for staining with DAPI (4’,6-diamidino-2-phenylindole,
dihydrochloride), as opposed to PI, effectively avoiding treatment with an RNase, thereby
speeding up the procedure. DAPI is a membrane impermeable dye that intercalates AT rich
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sequences, intercalating DNA but not RNA, which does not contain thymine43. The detergent
NP-40 permeabilizes the cell membrane and allows for the intercalation of DAPI to the DNA.
Cells were seeded at 200,000 cells/mL/well in 24-well plates and treated with RS1-208b
for 24 hours. Hydrogen peroxide, untreated cells, and DMSO treated cells were included as
positive, negative, and vehicle controls, respectively. Following 24 hours of treatment, cells were
collected in a 5mL culture tube and centrifuged for 5 minutes at 1200rpm. The supernatant was
decanted and the cell pellet re-suspended in 200µL of the NIM-DAPI solution. The tubes were
incubated for 5 minutes in the dark at room temperature then 300µL PBS was added to each tube
prior to reading by flow cytometry equipped with a 405nm Solid-State Violet Diode laser to
excite DAPI and the emission was detected through the FL9 channel. Below are graphical
representations of the histograms obtained. G0/G1 represents diploid cells (2n); S represents
cells undergoing DNA synthesis (2n-4n); G2/M represents tetraploid cells (4n); and <G0/G1
represents apoptotic bodies containing fragments of DNA.
Curcumin and some of its structural analogs have been reported to induce cell cycle arrest
at the G2/M phase31,33. RS1-208b shows no appreciable arrest at the G2/M phase, compared to
vehicle. However, there is a significant (p < 0.05) increase in the <G0/G1 phase in the RS1-208b
treated cells, and a significant (p = 0.05) decrease in the G0/G1 phase, compared to vehicle.
Given the rapid replication rates of the cell lines used for this assay, it is possible that the time
point selected masks the effect on the cell cycle the compounds has on these cell lines. An earlier
time point might demonstrate an arrest at the G2/M phase due to the effect of the compound, and
if the damage induced by the compound is irreparable, the arrested cells initiate apoptosis, which
we are able to detect at 24 hours.
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Figure 3. RS1-208b Does Not Induce Cell Cycle Arrest
a) Bar graphs represent average values (biological replicates = 3) of histograms. The <G0/G1 in RS1-208b treated
cells was significantly higher than the DMSO control, indicating that the compound induces apoptosis in CCRFCEM cells after 24 hours of treatment. The G0/G1 peak was significantly smaller (p < 0.05) in the RS1-208b treated
cells than DMSO control, suggesting that cells did not re-enter the cell cycle following mitosis. The percentage of
cells in the S phase and G2/M phase was similar between RS1-208b treated cells and DMSO control. Standard
deviations were included for the <G0/G1 peak.
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b) Bar graphs represent average values (biological replicates = 3) of histograms. The <G0/G1 in RS1-208b treated
cells was significantly higher than the DMSO control, indicating that the compound induces apoptosis in HL-60
cells after 24 hours of treatment. The G0/G1 peak was significantly smaller (p < 0.05) in the RS1-208b treated cells
than DMSO control, suggesting that cells did not re-enter the cell cycle following mitosis. The percentage of cells in
the S phase and G2/M phase was similar between RS1-208b treated cells and DMSO control. Standard deviations
were included for the <G0/G1 peak.
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c) Bar graphs represent average values (biological replicates = 3) of histograms. The <G0/G1 in RS1-208b treated
cells was significantly higher than the DMSO control, indicating that the compound induces apoptosis in RAMOS
cells after 24 hours of treatment. The G0/G1 peak was significantly smaller (p < 0.05) in the RS1-208b treated cells
than DMSO control, suggesting that cells did not re-enter the cell cycle following mitosis. The percentage of cells in
the S phase and G2/M phase was similar between RS1-208b treated cells and DMSO control. Standard deviations
were included for the <G0/G1 peak.

The formation of apoptotic bodies was concentration dependent in the CCRF-CEM cell
line (p < 0.05). Interestingly, the results from CCRF-CEM and RAMOS cell lines indicate that
RS1-208b does not affect the S or G2/M phases, as there was no appreciable difference in these
phases across treatments. However, in the HL-60 cell line there was a decrease in the percentage
of cells in both the S and G2/M phase.
Though we did not observe an arrest in the progression through the cell cycle in any of
the cell lines tested, we were able to narrow down the pathway of cell death treatment with RS1208b initiated.
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4. Evaluating Apoptosis Induced by R1-208b
4.1 Assessment of Phosphatidylserine Externalization Induced by RS1-208b
Phosphatidylserine (PS) is a phospholipid that, in viable cells, is only found on the inner
leaflet of the mammalian cell membrane44,45. The asymmetry is maintained by ATP-dependent
flippases that quickly internalize PS that has been exposed to the outer leaflet46. Externalization
of PS occurs when a cell is undergoing apoptosis and it serves to recruit macrophages47 to
facilitate the cell’s degradation and subsequent removal from the system. During apoptosis,
calcium is released from the endoplasmic reticulum and mitochondria which activates Ca+2dependent scramblases46,47 that externalize the PS and mark the cell for degradation by
macrophages48. Furthermore, under apoptotic conditions, cells decrease ATP production, leading
to the inactivation of ATP-dependent flippases that would otherwise internalize PS.
The Annexin V assay was used in order to confirm the results of the cell cycle assay that
the cytotoxicity induced by RS1-208b was occurring through apoptosis. Annexin V is a small
protein with high affinity to PS47. The assay employs an Annexin V that is conjugated to FITC
(fluorescein isothiocyanate), a fluorescent dye, which, upon Annexin V binding of PS, undergoes
a conformational change in structure that allows for excitation and emission. Annexin V is
impermeable to the cell membrane only capable of binding to externalized PS47, thus the
percentage of cells fluorescing green are considered to be undergoing cell death through
apoptosis. The assay also makes use of PI (which intercalates DNA and double stranded RNA in
cells whose membranes have become compromised43) to distinguish between early apoptosis
(only externalization of PS) and late apoptosis (externalized PS and also compromised
membrane). Furthermore, cells that only fluoresce red (stained only with PI) are thought to have
experienced cell death through a mechanism other than apoptosis.
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Cells were seeded at 200,000 cells/mL/well in a 24-well plate and treated with RS1-208b
for 24 hours. Hydrogen peroxide treated cells, untreated cells, and DMSO treated cells were used
as positive, negative, and vehicle controls, respectively. Following 24 hours of treatment, cells
were collected in 5mL culture tubes and centrifuged for 5 minutes at 1200rpm. The supernatant
was discarded and the cells were re-suspended in 100µL of ice-cold 1x Binding Buffer
containing 1µL of Annexin V-FITC and 2.5µL of PI. The tubes were then incubated on ice in the
dark for 15 minutes. After the incubation, 400µL of ice-cold 1x Binding Buffer was added to
each tube and read using a flow cytometer equipped with a 488nm OPSL Sapphire laser. FITC
signal was detected through the FL1 channel and propidium iodide was detected through the FL2
channel. Below are graphical representations of the percentage of cells stained with either FITC
(cells with externalized PS; early and late apoptosis) or only PI.
The results from the Annexin V assay confirm that RS1-208b induces apoptosis in
hematological cancer cell lines. However, they also point to a non-apoptotic mechanism of cell
death that is also induced by the compound. There was a correlation between increasing the
concentration of RS1-208b and externalization of phosphatidylserine that was not apparent
between the concentration of RS1-208b and the other mechanism of cell death (presumably,
necrosis).
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Figure 4. RS1-208b Induces Phosphatidylserine Externalization
a) Bar graphs (± standard deviation) represent average values (biological replicates = 3) of the percentage of Jurkat
(ALL) cells stained with FITC (cells undergoing apoptosis) and cells stained with only PI. RS1-208b induces
phosphatidylserine externalization (p < 0.05) in a concentration dependent manner in Jurkat cells.
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b) Bar graphs (± standard deviation) represent average values (biological replicates = 3) of the percentage of HL-60
(ALL) cells stained with FITC (cells undergoing apoptosis) and cells stained with only PI. In HL-60 cells, RS1-208b
induces the externalization of phosphatidylserine. The difference between RS1-208b treated and vehicle treated is
statistically significant (p < 0.05).
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c) Bar graphs (± standard deviation) represent average values (biological replicates = 3) of the percentage of
RAMOS (ALL) cells stained with FITC (cells undergoing apoptosis) and cells stained with only PI. RS1-208b
induces phosphatidylserine externalization (p < 0.05) in RAMOS cells in a concentration dependent manner.

The molecular structure of RS1-208b has been described as having inhibitory effects on
the release of inflammatory cytokines29. Despite this, the other mechanism of death induced
points to the possibility RS1-208b to elicit an inflammatory response in vivo. Though chronic
inflammation has been linked to carcinogenesis, acute inflammation, such as that caused by
chemotherapy, could have beneficial effects by amplifying the cell death and rapidly clearing
cellular debris from the tumor site, leading to a reduction in tumor size.

4.2 Assessment of Mitochondrial Involvement in Apoptosis Induced by RS1-208b
The mitochondria is an important organelle that generates ATP for the cell to use49. ATP
generation depends on the mitochondria’s ability to establish and maintain a transmembrane
potential50. The electron transport chain is responsible for releasing protons into the
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mitochondria’s transmembrane space, which, compared to the mitochondrial matrix and the
cytoplasm, is relatively positively charged.
The loss of mitochondrial transmembrane potential is observed at early time points
during apoptosis via the intrinsic pathway49,50. Through this pathway, pro-apoptotic proteins of
the BCL2 family of proteins are thought to oligomerize50 along the outer membrane of the
mitochondria and form pores or channels through which protons and other contents sequestered
in the intermembrane space of the mitochondria are released. This results in the loss of the
transmembrane potential established through the electron transport chain, and consequently, the
loss of ATP generation. Furthermore, cytochrome c (and stored calcium cations) are also
released from the intermembrane space and can act as second messengers and participate in the
apoptotic signaling pathway49,50.
The mitochondrial depolarization assay JC-1 uses a cationic dye (5’,6,6’-tetrachloro1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide) capable of emitting fluorescence of two
different wavelengths, depending on its aggregation status. The dye is permeable to the
mammalian cell membrane as well as the mitochondrial membranes. In healthy, viable cells, the
cationic dye penetrates the mitochondrial membranes and deposits itself in the mitochondrial
matrix (negatively charged), where it forms aggregates in a concentration dependent manner.
Dye that isn’t found in the matrix is found in the cytosol (negatively charged), where it is unable
to form aggregates due to the cytosol’s higher relative volume, which decreases the relative
concentration of the JC-1. However, in cells undergoing apoptosis, the flux of dye between the
matrix and cytosol increases due to oligomerization of Bax/Bak proteins and the subsequent
depolarization of the mitochondria, resulting in an increase of monomer to aggregate signal.
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Cells were seeded at 200,000 cells/mL/well in 24-well plates and treated with RS1-208b
for 5 hours. Hydrogen peroxide treated cells, untreated cells, and DMOS treated cells were used
as positive control, negative control, and vehicle control, respectively. Cells were collected into
5mL culture tubes and centrifuged for 5 minutes at 1200rpm. The supernatant was decanted and
the cells re-suspended in 500µL of PBS along with 5µL of the JC-1 dye, and incubated at 37ºC
for 0.5 hours. The cells were then analyzed using a flow cytometer with a 488nm OPSL Sapphire
laser to excite the JC-1 and the emission of monomers and aggregates was detected through the
FL1 and FL2 channels, respectively. The graphs below represent the monomer/aggregates ratios
to indicate the polarization status of the mitochondria; a higher ratio indicates the mitochondria
has become depolarized.
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Figure 5. RS1-208b Induces Mitochondrial Depolarization
a) Bar graphs represent the ratio (± standard deviation) of monomers/aggregates (biological replicates = 3).
Mitochondrial depolarization is observed in Jurkat following 5 hours of treatment with RS1-208b, though the
difference in this experiment was not statistically significant.
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b) Bar graphs represent the ratio (± standard deviation) of monomers/aggregates (biological replicates = 3).
Statistically significant (p < 0.05) mitochondrial depolarization is observed in HL-60 following 5 hours of treatment
with RS1-208b.
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c) Bar graphs represent the ratio (± standard deviation) of monomers/aggregates (biological replicates = 3).
Statistically significant (p < 0.05) mitochondrial depolarization is observed in RAMOS following 5 hours of
treatment with RS1-208b.
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Mitochondrial depolarization was assessed in three different hematological cancer cell
lines (Jurkat, HL-60, and RAMOS). Though in Jurkat the results did not achieve statistical
significance, there was an appreciable increase in the mitochondrial depolarization of the cells
treated with RS1-208b compared to vehicle control. In the HL-60 cell line, the mitochondrial
depolarization induced by RS1-208b was statistically significant when compared to DMSO. In
the RAMOS cell line, the mitochondrial depolarization was shown to be dose dependent, with
both concentrations of RS1-208b tested being statistically significant. The mitochondrial
depolarization results suggest that RS1-208b induces apoptosis through the intrinsic pathway in
the hematological cancer cell lines tested.

4.3 Assessment of the Involvement of Caspase 3 in RS1-208b Induced Apoptosis
Caspases (cysteine-dependent aspartate-directed proteases) are enzymes activated from
zymogens that are recruited through the apoptosis signaling pathway to cleave a large number of
target molecules at specific sites and aid in the degradation of proteins51. Caspases are generally
classified into three categories: inflammatory caspases, initiator caspases, and executioner
caspases50,51. The activation of individual caspases depends on the specific pathway of cell death,
though there is experimental data which suggests cross-talk between cell death pathways51.
The activation of effector caspases is downstream of mitochondrial depolarization,
following cytochrome c and calcium release from the intermembrane space into the cytosol50,51.
Cytochrome c and Apaf-1 molecules combine to form the apoptosome in the presence of
calcium50. The apoptosome then cleaves pro-caspase-9 and activates caspase-349,50. The
activation of Capase-3 in response to treatment with RS1-208b provides a direct link between the
RS1-208b induced mitochondrial depolarization observed at 5 hours and the cell death through
apoptosis observed following 24 hours of treatment.
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The Caspase-3 assay uses a substrate composed of a fluoregenic DNA dye that is
permeable to the cell membrane and is coupled to a caspase-3 recognition site. Activated
caspase-3 in cells undergoing apoptosis cleaves the substrate, releasing the fluoregenic dye,
which translocates to the nucleus, where it binds to DNA and emits fluorescence following
excitation with an OPSL Sapphire laser.
Cell were seeded at 200,000 cells/mL/well in a 24-well plate and treated with RS1-208b
for 7 hours. Hydrogen peroxide treated cells, untreated cells, and DMSO treated cells were used
as positive control, negative control, and vehicle control, respectively. Cells were collected into
5mL culture tubes and centrifuged for 5 minutes at 1200rpm. Following centrifugation, the
supernatant was decanted and the cells re-suspended in 200µL of PBS and incubated with 5µL of
the substrate stock solution for 30 minutes in the dark at room temperature. PBS (200µL) was
then added to each tube and the tubes assessed with a flow cytometer using a 488nm OPSL
Sapphire laser to excite the fluoregenic dye. The FL1 channel was used for the detection of
fluoregenic dye that was released from the substrate by caspase 3 and bound to DNA. Below are
bar graphs representing the percentage of the population in each treatment group that had
activated caspase 3.
Caspase 3 was activated in both HL-60 and RAMOS cell lines, though the effect was
more pronounced in RAMOS. Compared to the vehicle control, the results were shown to be
statistically significant (p < 0.05). This places caspase 3 activation directly down-stream of
mitochondrial depolarization and confirms the intrinsic pathway of apoptosis.
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Figure 6. RS1-208b Induces Caspase 3 Activation
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a) Bar graphs represent average (± standard deviations) of the percentage of cells with active caspase 3 (biological
replicates = 3). RS1-208b induced the activation of caspase 3 in HL-60 at 7 hours of treatment and the induction is
statistically significant (p < 0.05), compared to DMSO. The results indicate the intrinsic pathway of apoptosis is
induced by RS1-208b.
b)

RAMOS caspase 3 (7hours)
100
90

% of cell population

80
*

70
60
50
40
30
20
10
0
Untreated

DMSO

RS1-208b (1µM)

Hydrogen Peroxide

b) Bar graphs represent average (± standard deviations) of the percentage of cells with active caspase 3 (biological
replicates = 3). RS1-208b induced the activation of caspase 3 in RAMOS at 7 hours of treatment and the induction is
statistically significant (p < 0.05), compared to DMSO. The results indicate the intrinsic pathway of apoptosis is
induced by RS1-208b.
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4.4 Assessment of the Involvement of Caspase 8 in RS1-208b Induced Apoptosis
Caspase-8 is one of two initiator caspases with a death effector domain44,51. It is recruited
and trans-activated following ligand biding to a death receptor at the surface of the cell
membrane44. This pathway of apoptosis (initiated by ligand binding to death receptor) is referred
to as the extrinsic pathway of apoptosis, and generally bypasses mitochondrial depolarization at
the early hours50,52. Caspase-8 activation generally peaks at 4 hours following treatment with
extrinsic apoptosis inducing compounds52.
The Caspase-8 assay uses a substrate conjugated to FITC. In cells undergoing apoptosis
through the extrinsic pathway, activated Caspase-8 activated at the early hours recognizes and
cleaves the substrate, allowing for the detection of the conjugated FITC dye by fluorescent
means.
Cells were seeded at 200,000 cells/mL/well in 24-well plates and treated with RS1-208b
for 4 hours. Untreated cells and DMSO treated cells were included as negative and vehicle
controls. During the optimization of the protocol we were unable to find a suitable positive
control for Caspase-8 activation. Following treatment, 300µL of each well were collected into
5mL culture tubes and incubated with 1µL of the Caspase-8 substrate for 1 hour at 37ºC. Culture
tubes were then centrifuged for 5 minutes at 1200rpm and the supernatant decanted. Cells were
washed with the wash buffer provided in the staining kit, centrifuged (5 minutes at 1200rpm),
and the supernatant decanted, twice. Flow cytometry analysis was done using a flow cytometer
with a 488nm OPSL Sapphire laser to excite FITC, and the FL1 channel to detect emission of
fluorescence. Cells stained with FITC indicate activation of caspase-8 and implicate the extrinsic
pathway of apoptosis. The results are represented in bar graphs below.
The activation of caspase-8 by RS1-208b at 4 hours of treatment was not statistically
significantly different when compared to the DMSO vehicle control, indicating the extrinsic
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pathway of apoptosis is not a pathway involved in the observed cell death. This result, along with
the caspase-3 data, implicates the mitochondria-mediated intrinsic pathway as the major (if not
only) pathway of programmed cell death induced by RS1-208b in hematological cancer cell
lines.

RAMOS-Caspase 8 (4 hours)
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Figure 7. RS1-208b Does Not Induce the Activation of Caspase 8
Bar graphs represent the average values (± standard deviations) of the percentage of cells with activated Caspase-8
(biological replicates = 3) following 4 hours of treatment. Caspase-8 activation was not statistically significantly
different (p > 0.05) in RS1-208b treated cells compared to DMSO.

4.5 Assessment of Tumor Necrosis Factor α (TNFα) Production
The like curcumin14, molecular structure of RS1-208b has been reported to inhibit the
production of pro-inflammatory cytokine IL-629. Analysis of the Annexin V assay pointed to
necrosis as a possible secondary pathway of cell death induced by RS1-208b, a pathway which
could elicit an inflammatory response. We independently assessed whether RS1-208b lead to the
production of a different pro-inflammatory cytokine (TNFα) that is also involved in the extrinsic
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pathway of apoptosis and necrosis53,54. RS1-208b was not shown to induce the activation of the
extrinsic pathway of apoptosis at 4 hours, therefore we assumed that if TNFα was released in
response to RS1-208b, the cell death pathway it would trigger would be necrosis. This would
help us determine the potential inflammatory response RS1-208b could elicit in vivo by
identifying the secondary mechanism of cell death we observed in the Annexin V assay.
Necrosis and inflammation play an important and somewhat curious roles in tumor
development54. On the one hand, tumor cells that underdo necrosis in response to
chemotherapeutics lead to an acute inflammatory response that quickly removes them from the
system. However, prolonged or chronic inflammation provides an ideal milieu for tumor
development. In this way, cell death of a small sub-set of the tumor population through necrosis
could prove to be beneficial as long as treatment with RS1-208b does not lead to the perpetual
production of inflammatory cytokines.
The Thermo Fisher Scientific Human TNFα ELISA kit (EH3TNFa) was used to
determine the production of TNFα in Jurkat cells in response to RS1-208b. Enzyme-linked
immunosorbent assays (ELISA) offer a quick and easy way to quantify soluble proteins using a
spectrophotometer and a ladder of standards with known concentrations. This particular assay
uses a 96-well plate that has been pre-coated with an antibody against human TNFα. For this
assay, 100,000 cells/mL were treated with 0.5µM RS1-208b, 1µM RS1-208b, 1% v/v DMSO, or
left untreated. Cells were collected into micro-centrifuge tubes following 6 hours of incubation
with RS1-208b and centrifuged for 5 minutes at 1200rpm. The supernatant was collected into
new micro-centrifuge tubes and stored at -80ºC overnight. The protocol provided by Thermo
Fisher Scientific was followed with no modifications. Briefly, the assay consists of adding the
supernatant (presumably containing cytokines released in response to treatment with RS1-208b)
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collected to the wells pre-coated with the antibody against TNFα. A biotinylated antibody is then
added, followed by horseradish peroxidase conjugated streptavidin. Finally, a color changing
substrate is added before reading through a spectrophotometer, reading at a wavelength of
450nm. Optimization of the protocol failed to reveal a trustworthy positive control. Untreated
cells and DMSO treated cells were used as negative and vehicle controls, respectively.

Jurkat ELISA (6 hours)
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Figure 8. RS1-208b Does Not Lead to the Production and Release of TNFα
Treatment of Jurkat cells (biological replicates = 3) does not lead to the production and subsequent release of proinflammatory cytokine TNFα. Points on the graph represent average values.

Treatment of Jurkat cells with RS1-208b at both concentrations resulted in a slight
(though, not statistically significant) inhibition of TNFα production and release, compared to
DMSO, though the inhibition did not appear to be concentration dependent. The data indicates
that RS1-208b does not induce TNFα cytokine release, and would, therefore, not likely elicit a
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sustained pro-inflammatory response in vivo that would lead to chronic inflammation around the
tumor site.
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5. Identifying the Molecular Pathway of RS1-208b Induced Apoptosis
5.1 Transcriptome Analysis Using AmpliSeq
Recent advances in RNA sequencing technology have made analysis of transcriptomes
economically feasible and have drastically increased the throughput capacity compared to
conventional microarrays and RT-qPCR55. Though most RNA-sequencing systems employ a
similar fluorescence based method of detection, AmpliSeq uses Ion Torrent Proton next
generation sequencing (NGS) technology to sequence transcriptomes56, allowing for decreased
background noise on longer transcripts. Briefly, the Ion Torrent Proton NGS uses a
semiconductor to detect changes in pH as a nucleotide is added to the pre-amplified transcripts
and converts it into an electrical signal56. Molecular barcodes enable mapping onto target
sequence library56.
Comparison of Illumina HiSeq (one of the most widely used RNA-seq platforms) and Ion
Torrent Proton sequencing platforms using standard RNA reference samples found strong
concordance (Pearson’s r = 0.9256). Furthermore, AmpliSeq outperforms Illumina HiSeq for
highly abundant genes while capturing similar patterns of gene expression56. AmpliSeq’s high
accuracy and sensitivity for whole transcriptome analysis is on par with some of the most
advanced and widely used RNA-sequencing technologies but at a fraction of the cost56.
HL-60 cells (400,000 cells/2mLs/well in a 24-well plate) treated with either 2µM RS1208b or PEG-400 (0.3% v/v) for 6 hours (biological replicates = 3). The cell line and time point
were selected for direct comparison against the Broad Institute’s Connectivity Map (cMAP).
PEG-400 was selected as the vehicle control to minimize the effect contributed to the vehicle
(see Figure 17.). Following treatment, cells were collected into microcentrifuge tubes and
centrifuged for 5 minutes at 1400rcf. Cells were then washed with ice cold PBS and centrifuged
(5 minutes at 1400rcf), twice. PBS was aspirated and the dry pellet stored at -80ºC overnight.
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The following morning, RNA was extracted using Qiagen’s RNeasy Mini Kit (74104), following
the protocol provided, along with the optional Qiashredder (79654) and DNAse II digestion
steps, to maximize RNA extraction and minimize DNA contamination. RNA quantification and
purity assessment was performed using the NanoDrop. The results for individual replicates are
summarized below. A260:A280 ratios above 2.0 and A260:A230 ratios above 1.7 were taken to
indicate successful RNA extraction and purity of RNA. RNA sequencing was performed using
Ion AmpliSeq Transcriptome Human Gene Expression Kit (ThermoFisher Scientific, A26325).

Table 4. RNA Extraction Results for AmpliSeq Analysis Indicate High Purity RNA
Sample ID Sample Volume ng/µL 260/280 260/230
PEG-400-1 30µL
54.60
2.14
1.71
PEG-400-2 30µL
50.91
2.18
1.84
PEG-400-3 30µL
42.88
2.14
1.86
RS1-208-1 30µL
49.87
2.19
1.98
RS1-208-2 30µL
43.99
2.16
1.90
RS1-208-3 30µL
45.08
2.23
1.87

Analysis of AmpliSeq data revealed 604 genes that were more than 2-fold differentially
regulated in HL-60 cells treated with RS1-208b for 6 hours. Of those 604 genes, 421 genes were
more than 2-fold up-regulated and 183 genes were more than 2-fold down regulated. Table 5 and
Table 6 summarize the genes that were more than 5-fold differentially regulated in response to
treatment with RS1-208b for 6 hours compared to the vehicle control.
The most up-regulated gene in response to treatment with RS1-208b was HMOX1 (heme
oxygenase 1), a gene integral in the regulation of oxidative stress57. A quick overview of the
most up-regulated genes suggests that RS1-208b induces the transcription of a large number of
heat shock genes, suggesting that protein misfolding might play a role in the cell death induced
by RS1-208b. ATF3 (activating transcription factor 3), a transcription factor that is important in
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the signaling pathway of the endoplasmic reticulum stress response58, was one of the most upregulated genes in response to RS1-208b. Preliminary analysis of the AmpliSeq data using only
the most up-regulated genes pointed towards RS1-208b inducing cell death through oxidative
and endoplasmic reticulum stress.

Table 5. List of Genes That Were More Than 5-fold Up-Regulated in Response to
Treatment with RS1-208b for 6 Hours Compared to Vehicle Control
ID
HMOX1
HSPA6
HSPA1B
HSPA1A
BAG3
DUSP1
ATF3
DNAJA4
DNAJB1
CHAC1
DNAJB4
CDKN1A
PPP1R15A
HSPH1
FOSB
SERPINH1
FOSL1
SESN2
ADM
PMAIP1
USPL1
ZFAND2A
RGS2
DDIT4
PTGS2
HBEGF
LINC00641
EGR1
IER5

EntrezGene FC
pValue
3162
700.2631 2.14E-237
3310
518.3819 2.21E-150
3304
425.3722 1.89E-136
3303
231.6072 4.95E-134
9531
139.2204 5.56E-127
1843
100.1904
8.11E-45
467
96.70101 4.97E-100
55466
85.74082 7.98E-136
3337
53.93731 1.57E-147
79094
51.29061 1.98E-156
11080
30.96209
1.69E-43
1026
30.88426
4.53E-34
23645
29.9688 1.15E-150
10808
24.41394 2.07E-180
2354
23.85085
2.11E-56
871
22.13491
1.90E-22
8061
21.49553
2.87E-31
83667
21.33146 3.75E-149
133
20.85347
8.81E-81
5366
20.65687
3.90E-89
10208
17.46388
2.95E-36
90637
17.41307
1.23E-41
5997
17.39775
2.05E-18
54541
17.21004 2.72E-120
5743
12.52229
6.98E-18
1839
12.20392
6.91E-48
283624
9.893837
3.77E-41
1958
9.874298
8.25E-11
51278
9.831486
6.89E-57
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CHORDC1
VEGFA
DNAJA1
HSP90AA1
TNFRSF10D
MRPL18
HMGCS1
TUFT1
BCAS2
MXD1
TOR1AIP2
HSPA8
HERPUD1
SPATA2

26973
7422
3301
3320
8793
29074
3157
7286
10286
4084
163590
3312
9709
9825

9.148122
9.014776
8.961766
8.606375
8.404733
8.290333
8.242085
7.902703
7.550944
7.230572
7.042911
6.808084
6.688471
6.247421

3.46E-50
9.01E-71
2.31E-126
1.23E-103
3.16E-36
1.67E-96
2.85E-85
1.99E-36
7.19E-106
9.79E-76
5.83E-33
2.01E-92
1.25E-88
6.76E-46

Table 6. List of Genes That Were More Than 5-Fold Down-Regulated in Response to
Treatment with RS1-208b for 6 Hours Compared to Vehicle Control
ID
EntrezGene 1/FC
p-Value
HIST1H2BC
8347 10.03775 6.98E-12
THEMIS2
9473 8.676445 1.94E-40
HIST1H1D
3007 8.09482 1.77E-26
HIST1H3C
8352 6.744863 1.15E-67
NFE2
4778 6.358766 4.85E-32
GFI1
2672 5.954293 2.20E-85
P2RY2
5029 5.742057 4.69E-67
CEBPE
1053 5.448144 1.43E-51
MYC
4609 5.133881 4.57E-46
HIST1H2BF
8343 5.046388 1.55E-13

Data analysis of the most down-regulated genes in response to treatment with RS1-208b
did not implicate a particular mechanism of cell death. However, it is important to note that RS1208b down-regulated MYC, an oncogene that is found heavily dysregulated in the majority of
leukemia and lymphoma cases of childhood cancer59,60. MYC is a transcription factor of prosurvival genes and is partially responsible for a cancerous cell’s rapid progression through the
cell cycle60. Down-regulation of MYC could play an important role in RS1-208b induced cell
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death by down-regulating MYC pro-survival gene targets and allowing the cell’s response to
shift to a pro-apoptotic response.

5.2 AmpliSeq Data Mapping onto Gene Ontology
Gene Ontology (http://geneontology.org/page/go-enrichment-analysis) is an online tool
used to provide enrichment analysis on a particular set of genes. Inputting the IDs of the
differentially regulated genes, we were able to identify which biological processes were most
affected by treatment with RS1-208b. Figure 9 represents the number of genes differentially
regulated in RS1-208b treated HL-60 cells in each biological process, listed by GO term. Table 7
summarizes the percentage of annotated genes in each biological process that were significantly
up- or down-regulated in response to RS1-208b.
The biological pathways with the highest number of genes differentially regulated in
response to RS1-208b were (in descending order by GO term): negative regulation of
transcription, response to topologically incorrect protein folding, response to temperature
stimulus, protein folding, and intrinsic apoptotic signaling pathway in response to endoplasmic
reticulum stress.
The large number of significantly up-regulated heat shock genes (Table 5) are heavily
involved in four-out-of-the-five processes with the most number of differentially regulated
genes. Shifting the focus from total number of genes differentially expressed per biological
process to the percentage of annotated genes in each pathway that were differentially expressed
in response to RS1-208b, the PERK-mediated unfolded protein response stands out as the main
biological process (that leads to apoptosis) affected by RS1-208b at 6 hours. This process is
upstream of the up-regulation of many heat shock proteins, but most importantly, upstream to the
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress.
42

RS1-208b
mitotic spindle assembly checkpoint
cellular iron ion homeostasis
positive regulation of kidney developmen...
labyrinthine layer morphogenesis
vascular smooth muscle cell differentiat...
organ or tissue specific immune response
antibacterial humoral response
amino acid transmembrane transport
cellular response to arsenic-containing ...
regulation of inclusion body assembly
regulation of vasodilation
response to alkaloid
response to purine-containing compound
extrinsic apoptotic signaling pathway vi...
positive regulation of vasculature devel...
PERK-mediated unfolded protein response
receptor-mediated endocytosis
nucleosome assembly
regulation of transcription from RNA pol...
response to hypoxia
regulation of protein serine/threonine k...
intrinsic apoptotic signaling pathway in...
protein folding
response to temperature stimulus
response to topologically incorrect prot...
negative regulation of transcription

0

2

4

6

8

10

12

Figure 9. Number of Genes Differentially Regulated Listed by GO Term
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Table 7. GO Pathways with the Most Number of Genes Significantly Affected by
Treatment with RS1-208b
GO.ID
GO:0042312
GO:0090083
GO:0036499
GO:0002251
GO:0035886
GO:0060713
GO:0090184
GO:0070059
GO:0071243
GO:0003333
GO:0019731
GO:1904018
GO:0043618
GO:0009266
GO:0008625
GO:0035966
GO:0014074
GO:0043279
GO:0006334
GO:0006457
GO:0006898
GO:0006879
GO:0007094
GO:0001666
GO:0071900
GO:0045892

Biological Process
regulation of vasodilation
regulation of inclusion body assembly
PERK-mediated unfolded protein response
organ or tissue specific immune response
vascular smooth muscle cell differentiat...
labyrinthine layer morphogenesis
positive regulation of kidney developmen...
intrinsic apoptotic signaling pathway in...
cellular response to arsenic-containing ...
amino acid transmembrane transport
antibacterial humoral response
positive regulation of vasculature devel...
regulation of transcription from RNA pol...
response to temperature stimulus
extrinsic apoptotic signaling pathway vi...
response to topologically incorrect prot...
response to purine-containing compound
response to alkaloid
nucleosome assembly
protein folding
receptor-mediated endocytosis
cellular iron ion homeostasis
mitotic spindle assembly checkpoint
response to hypoxia
regulation of protein serine/threonine k...
negative regulation of transcription

Annotated
5
5
12
5
5
5
5
34
9
10
10
20
31
88
32
96
37
31
50
114
68
25
27
95
160
376

Significant
3
3
6
2
2
2
2
13
3
3
3
5
6
14
5
14
5
4
6
13
6
2
2
7
10
17

%
60.0
60.0
50.0
40.0
40.0
40.0
40.0
38.2
33.3
30.0
30.0
25.0
19.4
15.9
15.6
14.6
13.5
12.9
12.0
11.4
8.8
8.0
7.4
7.4
6.3
4.5

The annotated genes in the PERK-mediated unfolded protein response are summarized in
Table 8. Also included in the table are the fold-count and p-values obtained from the AmpliSeq
analysis. Of the annotated genes in the PERK-mediated unfolded protein response, 8 were shown
to be up-regulated (FC > 1) and 1 down regulated. Six of the differentially regulated genes in this
pathway were significant (p < 0.05). In this biological process, ATF3 was the most up-regulated
gene in response to RS1-208b. Interestingly, some of its transcriptional targets are involved in

44

the intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress61
(annotated genes, fold-count and p-values are summarized in Table 9). The analysis of the
AmpliSeq data implicates RS1-208b as an inducer of the PERK-mediated unfolded protein
response.

Table 8. PERK-Mediated Unfolded Protein Response (GO:0036499)
Gene ID
ATF3
HERPUD1
NFE2L2
CXCL8
IGFBP1
EIF2S1
EIF2AK3
ASNS
CCL2
ATF4
DDIT3
HSPA5

FC
p-Value
96.70101 4.97E-100
6.688471
1.25E-88
1.720044
9.54E-08
*
*
0.056119 0.9618482
1.108594 0.4519698
2.34948 1.706E-11
1.133256 0.2013979
*
*
1.975024
6.52E-14
*
*
2.191538 3.591E-16

5.3 PERK-Mediated Unfolded Protein Response and Intrinsic Apoptosis
The endoplasmic reticulum (ER) is one of the important membrane-bound organelles
found in eukaryotic cells. The ER membrane, a single lipid bilayer, separates the cytosol from
the ER lumen, where much of the folding of over one-third of all proteins occurs 62,63. More
precisely, proteins that are bound for the ER, Golgi apparatus, lysosomes, secretion, or the
plasma membrane are translated into, and folded in, the ER lumen. These proteins contain a
signal sequence on the N-terminal that targets them to the ER membrane while they are being
synthesized on ribosomes62. The proteins are then co-translationally translocated into the ER
lumen through a translocon complex, where the signal sequence in cleaved and translation is
completed62.
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In the ER lumen, chaperones and co-chaperones aid in the folding of the polypeptide to
achieve the correct native tertiary structure of the protein by binding to client proteins and
avoiding foldings that are energetically unfavorable64. The process ensures that proteins destined
for the ER, Golgi apparatus, lysosomes, secretion, and the plasma membrane are properly folded
so they are able to function optimally further downstream.
However, in spite of the use of chaperones and co-chaperones, proper folding in the ER
lumen is achieved under 20% of the time62. Proteins in the ER lumen that are unable to achieve
the correct native structure are degraded through a process called ER-associated degradation
(ERAD)65,66. Through ERAD, proteins are retro-translocated from the ER lumen into the cytosol,
ubiquitinated, and degraded by the 26S proteasome65,66. A cell is understood to be experiencing
ER stress whenever the folding capacity in the ER lumen is overwhelmed, which generally leads
to an accumulation of misfolded proteins within the ER lumen67.
Protein homeostasis (proteostasis) is tightly regulated in eukaryotic cells68, with
translation, folding, and degradation of proteins all being important components that maintain it.
A cell experiences proteotoxic stress when it deviates from proteostasis; which occurs when one
or more components are not functioning properly.
The unfolded protein response (UPR) is a highly conserved molecular signaling pathway
that allows a cell to return to proteostasis (protein homeostasis) or undergo programmed cell
death following proteotoxic stress62,66,69–73. The UPR can be initiated by one of three
transmembrane proteins found in the ER that function as ER stress sensors: inositol-requiring
enzyme 1α (IRE1α), pancreatic endoplasmic reticulum kinase (PERK), or activating
transcription factor 6 (ATF6)62,69,74. IRE1α, PERK, and ATF6 all contain a luminal domain that
is capable of either directly or indirectly sensing misfolded proteins in the ER lumen when the
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misfolded protein levels surpass a threshold. The sensing of misfolded proteins leads to
activation of downstream pathways following oligomerization of the sensor that can help a cell
return to proteostasis or initiate programmed cell death71.
The ATF6 arm of the UPR initiates when ATF6 located on the ER lumen binds
misfolded proteins and translocates to the Golgi apparatus. There, it is subsequently cleaved by
proteases at the transmembrane domain, and the cytosolic portion of the protein (ATF(N)) is
released. The transcription factor then initiates transcription of UPR target genes that aim to
increase the size and folding capacity of the ER, and thus, restore proteostasis62,69,73.
IRE1α is associated with the ER chaperone BiP (binding immunoglobulin protein) on its
luminal portion62,73. When BiP becomes dissociated, upon the misfolded protein threshold being
reached in the ER lumen, IRE1α dimerizes and auto-transphosphorylates on the cytosolic tail,
leading to the activation of RNase domain62,73. Under mild ER stress conditions, the RNase of
IRE1α excises an intron 26 nucleotides long from the X-box protein 1 (XBP1) mRNA, which
leads to the translation of the mRNA. XBP1 translocates to the nucleus and initiates the
transcription of XBP1 targets that aim to restore proteostasis by increasing the size and folding
capacity of the ER. When the stress is prolonged, the RNase degrades select mRNAs with the
signal sequence in the N-terminal that targets them to the ER (including recently transcribed
chaperone and co-chaperone mRNAs) as well as miRNAs that inhibit the translation of proapoptotic proteins, thus increasing ER stress and initiating programmed cell death62,73.
The PERK-mediated branch of the UPR also begins with the dissociation of BiP from the
luminal domain of the ER transmembrane protein PERK following the accumulation of
misfolded proteins in the ER lumen, which allows for the dimerization of PERK on the cytosolic
domain and trans-autophosphorylation62,73,75. Phosphorylation of PERK at threonine residue 980
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and tyrosine residue 615 appear to be important for the initiation of this signaling pathway76.
Activated PERK phosphorylates eukaryotic translation factor 2α (eIF2α) at serine residue 5176–78
which provides cytoprotective effects by delaying global translation initiation to afford the
protein folding machinery ample time to re-fold misfolded proteins and return the cell to
proteostasis. Though phosphorylation of eIF2α can be accomplished by several eIF2 kinases76, in
the context of proteotoxic stress, PERK appears to be the dominant kinase (Ilustration 1).
The rate-limiting step in the synthesis of nascent polypeptides is translation initiation.
eIF2, along with the 40S ribosomal subunit and other translation initiation factors, forms the 43S
pre-initiation complex76–78. eIF2 facilitates translation initiation by recognizing start codons
during the scanning process of transcripts and bringing the translation machinery to start codons
when it is bound to GTP and Met-tRNAmet78. Following the recognition of the start codon, GTP
is hydrolysed and eIF2 is released from the translation machinery, at which point GDP is
exchanged for GTP, eIF2’s affinity for Met-tRNAmet is restored, and the pre-initiation complex
can form again to begin translation at the next start codon. Phosphorylation of the eIF2α subunit,
such as that observed during proteotoxic stress, inhibits the rapid exchange of GDP for GTP, and
thus reduces the machinery’s ability to initiate translation76,78.
Under proteotoxic conditions (such as those experienced during ER stress), despite global
translation being delayed, mRNAs with upstream open reading frames (uORFs) are
preferentially translated78. Activating Transcription Factor 4’s (ATF4) translation is selectively
upregulated during ER stress62,73,79, which initiates transcription of several UPR targets
(including chaperones, co-chaperones, and some XBP1 targets) to return to proteostasis62,69,74.
Human ATF4 contains two uORFs. Under normal conditions, the quick GDP-GTP turnover of
eIF2 allows for the re-formation of the pre-initiation complex by the time the scanning of the
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transcript reaches the second uORF, which overlaps the ORF of ATF4. The products from both
uORFs are quickly degraded. However, during ER stress conditions, the second uORF is
bypassed by the translation machinery as GDP-GTP exchange is inhibited, allowing for the
recognition of ATF4’s ORF and the initiation of translation at the correct start codon, leading to
increased expression levels of ATF4 as well as the transcription of its down-stream target genes,
such as GADD34, which de-phosphorylates eIF2α when the cell returns to proteostasis79, or
phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP168,79).
Sustained ER stress leads to the transcription of ATF3, a bZIP transcription factor, by
ATF476. ATF4/3 are capable of forming heterodimers and transcribe PMAIP158,76,80, whose
translated product (Noxa) has received recognition as an important mediator in a cell’s
commitment to apoptosis81,82 (Illustration 2).
PMAIP1 is translated into Noxa, a pro-apoptotic, Bcl-homology domain 3 (BH3)-only
member of the BCL2 family of proteins82 that selectively binds MCL-183, an anti-apoptotic
member of the same family. MCL-1 inhibits Bax (another pro-apoptotic member of the BCL2
family of proteins) oligomerization at the outer membrane of the mitochondria83,84. By targeting
MCL-1 for degradation, Noxa effectively allows for the oligomerization of Bax and leads to the
subsequent release of cytochrome c and calcium ions from the mitochondrial intermembrane
space and caspase-3 dependent apoptosis81,84–88 (Illustration 2 and Illustration 3). Silencing Noxa
attenuates the cell death induced by proteotoxic stressors, pointing to its crucial role in mediating
apoptosis under ER stress conditions89.
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1.

2.

Illustration 1. Activated PERK Phosphorylates eIF2α
1. (Right) Peptides with an N-terminal sequence targeting them for the ER are translocated into the ER lumen and
co-translationally modified. BiP normally binds the luminal domain of PERK when it is in excess (during
proteostatic conditions). 2. Upon detection of misfolded proteins (left), BiP disassociates from PERK and
participates in the retro-translocation of the misfolded protein. The misfolded protein becomes ubiquitinated and
marked as it returns to the cytoplasm in an ATP-dependent manner. PERK is then able to dimerize and autotransphosphorylate. Phosphorylated PERK then phosphorylates the eIF2α subunit, which inhibits GDP-GTP
exchange and thus delays global translation under ER stress conditions.
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2.

1.

Illustration 2. ATF4/3 Up-Regulate PMAIP1
1. Under normal conditions (right), the mitochondrial transmembrane potential is maintained by the electron
transport chain and cytochrome c is contained within the mitochondrial intermembrane space. MCL-1 inhibits Bak
oligomerization at the mitochondrial outer membrane. 2. Under ER stress conditions (left), ATF4 transcripts are
preferentially translated due to their uORFs. ATF4 transcribes ATF3, and they are thought to heterodimerize to
transcribe PMAIP1. Noxa is the translated product of PMAIP1, and is crucial in initiating the intrinsic pathway of
apoptosis when the cell is subjected to ER stress. Noxa selectively binds MCL-1, thus allowing oligomerization of
Bak and leading to the release of cytochrome c into the cytosol and mitochondrial membrane depolarization.
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2.

1.

Illustration 3. Phosphatidylserine Externalization and Caspase 3 Activation Following
Mitochondrial Depolarization
1. Under normal conditions (right), ATP-dependent flippases maintain phosphatidylserine asymmetry. 2. After the
intrinsic pathway of apoptosis is initiated by oligomerization of Bak, cytochrome c released into the cytosol, along
with Apaf-1, form the apoptosome, which leads to the activation of caspase-3. Also, cytochrome c acts as a ligand
for IP3R to release stored calcium ions from the ER lumen. The calcium ion increase in the cytosol activates
calcium-dependent scramblases that externalize phosphatidylserine.

Table 9. Intrinsic Apoptotic Signaling Pathway in Response to Endoplasmic Reticulum
Stress (GO:0070059)
Gene ID
BAX
SELK
UBE2K
TRAF2
MAP3K5
TRIB3
ERO1L
ERN2
DAB2IP
CASP12
TNFRSF10B
PPP1R15A
CHAC1
PMAIP1
BCL2

FC
0.849778
3.104602
1.861324
*
*
5.074816
*
*
*
*
2.300088
29.9688
51.29061
20.65687
0.789518
52

p-Value
0.1435573
1.01E-23
2.70E-08
*
*
3.65E-65
*
*
*
*
2.17E-09
1.15E-150
1.98E-156
3.90E-89
0.0978836

CASP4
BRSK2
APAF1
ERN1
PML
BBC3
DNAJC10
CEBPB
GSK3B
ITPR1
ATF4
AIFM1
TMBIM6
XBP1
BAG6
BAK1
DDIT3
ATP2A1

1.288813
*
1.884722
2.688022
0.913207
*
*
*
1.23268
1.11542
1.975024
0.873896
1.319751
1.918808
1.072066
0.863233
*
*

0.0178311
*
4.43E-08
5.28E-14
0.5029359
*
*
*
0.0701281
0.33162
6.52E-14
0.1059551
0.0037422
4.81E-20
0.5245356
0.1873349
*
*

ATF4, which initiates transcription of ATF3 (up-regulated 96-fold in response to RS1208b, see Table 9) and heterodimerizes with ATF3 to transcribe PMAIP158,78–80, which is
significantly up-regulated in response to RS1-208b (see Table 9). Its preferential translation
under ER stress conditions increases the mRNA levels of its target genes ATF3 and PMAIP1. Of
the genes involved in the intrinsic apoptotic signaling pathway in response to endoplasmic
reticulum stress (see Table 9), PMAIP1 (up-regulated 20-fold in response to RS1-208b) is crucial
for apoptosis to proceed8184–86,90. These three genes (ATF4, ATF3 and PMAIP1) are significantly
up-regulated in response to RS1-208b, and provide a link between the PERK-mediated unfolded
protein response (determined by GO enrichment analysis of the AmpliSeq data) and the intrinsic
pathway of apoptosis induced by RS1-208b in hematological cancer cell lines that our in vitro
assays had characterized.
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6. Identifying the Molecular Target of RS1-208b
6.1 Connectivity Map Analysis
The cMAP was first introduced by the Broad Institute of Massachusetts Institute of
Technology and Harvard University as a resource to help find connections between reference
drugs (perturbagens) and mechanisms of action91. The cMAP was generated using a small panel
of cell lines including MCF7 (breast cancer), PC3 (prostate cancer), HL-60 (AML), and SKML5
(melanoma)) and 164 perturbagens91, though both the number of cell lines and the number of
perturbagens have expanded since its initial implementation of cMAP. Gene expression profiles
were collected from human cell lines treated with distinct small molecule perturbagens91. The
collection is paired with a software to find patterns of gene expression that match the query and
returns the perturbagen that most closely resembles the mechanism of action as the small
molecule in question. Gene expression profiles in the collection were initially composed of
microarrays with the data normalized to the vehicle control, though the collection is also
compatible with whole transcriptome analysis. Two different time points were used in cMAP,
with 6 hours after start of treatment representing a relatively early time point and a later time
point, 12 hours after start of treatment, available for comparison91. We selected to use the 6 hour
data to compare the molecular signature of RS1-208b to the collection of perturbagens given that
we had characterized the intrinsic apoptotic pathway being activated by 5 hours.
The Broad Institute opted for a rank-based pattern matching system to avoid some of the
drawback of hierarchical clustering, which would require that all gene expression profiles come
from the same microarray platform91. This way, researchers are able to compare gene expression
profiles obtained by microarrays or transcriptome analyses. Gene expression profiles from cells
treated with novel small molecules are compared to the reference database and the output returns
a file with the perturbagens ranked from the ones that most closely resemble the expression
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profile in the query to the ones that have the least number of genes, either up- or down-regulated,
in common.

Table 10. Molecular Signature of RS1-208b Compared to Perturbagens in cMAP
Rank
1
2
3
4
5
6
7
8
9
10
11
12
404

cMap_drug
MG-13292–94
MG-26295
PUROMYCIN96
15-DELTA PROSTAGLANDIN J297
PARTHENOLIDE98
PIPERLONGUMINE99–101
DISULFIRAM102
SECURININE103
PHENOXYBENZAMINE
CELASTROL104
LANATOSIDE C105
WITHAFERIN A106
CURCUMIN

KS_p-Value
4.6E-72
8.58E-72
1.2E-71
2.07E-69
5E-62
6.68E-62
9.6E-59
1.5E-58
3.81E-54
3.14E-53
8.71E-51
1.22E-50
0.0000013

Table 10 ranks the perturbagens whose molecular signature is more like that of RS1208b’s. Of the top 12 compounds listed in the cMAP as being most similar to RS1-208b, 7 have
been described to induce proteotoxic stress92–106. This supports the GO enrichment analysis of the
biological pathways involved in apoptosis induced by RS1-208b by providing an upstream
molecular target. Moreover, MG-132 and MG-262, which have molecular signatures most like
that of RS1-208b induce cell death through a mechanism like RS1-208b by inhibiting the
proteasome directly92–95. Therefore, we hypothesized that the proteasome was the main
molecular target of RS1-208b and that the inhibition of the proteasome, and subsequent
proteotoxic stress, initiates the signaling pathway that culminates in noxa-dependent apoptosis.
Chaperones in the ER lumen aid in the folding of nascent polypeptides but also regulate
the decision to degrade terminally misfolded proteins64,107. Under ER stress conditions, ERAD
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pathways involve the dissociation of BiP from IRE1α and PERK after the levels of misfolded
proteins surpass the threshold that allows BiP to bind to terminally misfolded proteins65,66.
Though the exact mechanism by which misfolded proteins are retro-translocated is not
fully understood, OS-9, SEL1L, Derlin-1, and p97 are thought to be heavily involved in the
process62,65. OS-9 and BiP transport the misfolded protein in the ER lumen to the ER membrane
associated protein SEL1L. The misfolded protein is then retro-translocated through a channel
composed of Derlin-1 proteins by the ATP-dependent p9762. The misfolded protein is then
ubiquitinated through an E3 ubiquitin ligase with an ER transmembrane domain and tagged for
degradation by the 26S proteasome (Illustration 1).
The UPS is an important component of the ERAD which degrades many of the misfolded
proteins65,66. Following retro-translocation, the misfolded proteins are ubiquitinated and tagged
for degradation through lysine residues62. Ubiquitination begins with E1 (ubiquitin-activating
enzyme) activation of ubiquitin. Then E2 (ubiquitin-conjugating enzymes) transfers the activated
ubiquitin from E1 to the target substrate (in this case, the misfolded protein that has been retrotranslocated to the cytoplasm) through E3 (ubiquitin-protein ligase) binding of both E2 and
target substrate. The misfolded proteins are subsequently deubiquitinated by the 19S regulatory
particle prior to being catalytically cleaved by the 20S catalytic core particle.
Interference with the UPS has been shown to induce the UPR66,108, though the mechanism
by which the ER transmembrane proteins sense this interference is poorly understood. The use of
Bortezomib, a small molecule that irreversibly binds to and inhibits the 26S proteasome109, in the
clinical setting demonstrates the effect proteasome inhibitors can have in combating cancer by
selectively inducing apoptosis through the generation of proteotoxic stress. Proteasome
inhibition results in the rapid accumulation of poly-ubiquitinated proteins, which triggers the
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intrinsic pathway of apoptosis93,109, and due to cancer cells having higher protein turnovers they
tend to be especially susceptible to the proteotoxic stress induced. However, despite its
success109, there have been incidences of cells developing resistance to Bortezomib.

6.2 RS1-208b Inhibits the Proteasome Indirectly
Curcumin has recently been shown to circumvent acquired resistance to Bortezomib110,
suggesting that, given curcumin analogs’ improved cytotoxicity profile, combining RS1-208b
with other proteotoxic stressors could increase survival rates in high-risk cancer patients. One of
the many molecular targets proposed for curcumin, and for which there is experimental evidence,
is the proteasome11,16. In vitro evaluation of curcumin and several structural analogs revealed the
decreased proteasome function38.
The 26S proteasome is an important component of the ERAD that degrades misfolded
proteins from the ER lumen that have been tagged with a chain of ubiquitin molecules66.
Treatments with proteasome inhibitors increase proteotoxic stress and induce the unfolded
protein response that results in apoptosis58,66,79. There are two major components of the 26S
proteasome: the 19S regulatory particle and the 20S catalytic core. The 20S particle is
responsible for cleaving proteins marked for degradation while the 19S regulatory particle binds
these proteins and removes the poly-ubiquitin chain to increase efficiency of degradation111.
Though curcumin and some structural analogs were shown to decrease the function of the 26S
proteasome38, follow up research indicates that the 20S core particle’s catalytic activity is not
adversely affected, with its caspase-like, trypsin-like, and chymotrypsin-like functions not being
diminished following treatment with structural analogs of curcumin112. Instead, these analogs
affect the proteasome by inhibiting the deubiquitination activity of deubiquitinases112–114
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POH1, UCHL5115,116, and USP14117are three deubiquitinases localized to the 19S
regulatory particle that carry out the deubiquitinating activity of the 26S proteasome112. b-AP15
(3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one), a compound with similar
molecular structure to RS1-208b, was shown to specifically inhibit the deubiquitinating activity
of UCHL5 and USP14, two cysteine proteases associated with the 19S regulatory particle, but
not the metallo-protease POH1112. Cysteine proteases, such as UCHL5 and USP14, contain a
cysteine residue that is crucial for their catalytic function. It is thought that the thiolate in this
catalytically crucial cysteine residue could interact in a Michael Reaction with the β-carbon of
the α,β-unsaturated moiety113 of curcumin analogs. Like b-AP15 and other monoketone
curcumin analogs, RS1-208b contains two sites of conjugated α,β-unsaturated carbonyls118
capable of acting as Michael Acceptors in Michael Reactions113 with catalytic cysteine thiolates
in the enzymatic activity pocket of deubiquitinases, leading to proteotoxic stress and the UPR
(Figure 10).
Despite not directly inhibiting the catalytic activity of the 26S proteasome, the molecule
b-AP15 has been described as an inhibitor of the UPS113,112,118. Targeted inhibition of both
cysteine deubiquitinating enzymes UCHL5 and USP14 has been reported to lead to programmed
cell death114. The microarray analysis of the expression profile of cells treated with b-AP15 is
similar to those of proteasome inhibitors in cMAP112. Interestingly, b-AP15 selectively inhibits
the deubiquitinating activity of the proteasome-associated cysteine deubiquitinases but not the
overall deubiquitinating activity by cysteine proteases in the cytosol not associated with the 19S
regulatory particle112.
The molecular structure similarity between RS1-208b and b-AP15 (Figure 10) and the
gene expression profiles suggesting their molecular mechanisms of action are similar, we
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performed in silico experiments to compare their docking onto proteasome-associated cysteine
deubiquitinases. b-AP15 docks onto UCHL5 and USP14 (near Cys88 and Cys114, respectively)
to inhibit their deubiquitinating activity, presumably by inhibiting the catalytically active
cysteine residue in each deubiquitinase113,114,118.

Figure 10. Molecular Structures of RS1-208b and b-AP15
RS1-208b and b-AP15 share structural similarity and have β-carbonyls sterically accessible to interact with thiolates
in a Michael reaction.

Docking onto UCHL5 (PDB:3IHR118) was performed using Glide by Dr. Skouta’s Lab.
Comparison of docking scores between RS1-208b and b-AP15 (see Table 11) suggest RS1-208b
is a more specific ligand for the pocket surrounding the catalytically active cysteine residue on
UCHL5 (Figure 11a.). The functional groups on the aromatic rings and the aromatic rings
themselves interact with several key amino acids surrounding the groove around Cys88 that help
orient the β-carbonyl toward the cysteine residue (Figure 11b). The aromatic rings of RS1-208b
are involved in pi-pi stacking with the phenylalanine in position 165 and the tryptophan in
position 58. Moreover, hydrogen bonds form between the oxygen atoms on the functional groups
on the aromatic rings of RS1-208b and phenylalanine in position 163 and tryptophan in position
58 and between the oxygen atom of the ketone moiety of RS1-208b and histidine in position 164
(Figure 11c).
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Docking onto USP14 (PDB:2AYN) was performed using SiteMap by Dr. Skouta’s lab.
Docking scores comparing RS1-208b and b-AP15 indicate that for this docking site situated
around the catalytically active cysteine at position 114 are summarized in Table 12. For USP14,
b-AP15 is likely a better inhibitor of catalytic activity. Though RS1-208b can dock on the same
pocket, albeit it with lower affinity (Table 12), the likely orientation of the molecule positions
the β-carbonyl far from the Cys114 (Figure 12a). The effect of RS1-208b on USP14 is not as
clear but since both cysteine deubiquitinases must be inhibited in order for the accumulation of
poly-ubiquitinated proteins to occur112, our working hypothesis is that on USP14 RS1-208b
competes with ubiquitinated proteins for the site around Cys114 and in this way reduces its
capacity to effectively cleave ubiquitin chains from proteins targeted for proteasomal
degradation.
The in silico docking of RS1-208b onto proteasome-associated deubiquitinases provides
a molecular target for the compound that is directly upstream of the signaling pathway (PERKmediated unfolded protein response) that culminates in noxa-dependent apoptosis through the
up-regulation of PMAIP1 transcripts, mitochondrial depolarization, and caspase-3 activation.
RS1-208b occupies a groove that brings it in close proximity to the catalytic cysteine residue on
UCHL5. This could bring the β-carbonyl in close enough range to interact with the thiolate
functional group in Cys88 (Figure 11b.) via a Michael reaction that inactivates (reversibly) the
deubiquitinase. However, the in silico docking onto USP14 showed that RS1-208b has less
affinity for the pocket than b-AP15. Furthermore, the β-carbonyl of the compound is likely too
far to interact with the thiol group of Cys114 in a Michael reaction (Figure 12a).
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a)

Figure 11. In Silico Docking of RS1-208b onto UCHL5
a) RS1-208b fits into the groove surrounding the Cys88 residue of UCHL5. The electrostatic colored surface is of
UCHL5 is shown above to depict the groove where RS1-208b deposits itself.
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b)

b) Docking of RS1-208b onto the groove surrounding the catalytically crucial Cys88 brings the β-carbonyl (blue
arrow) in close proximity to the thiolate (yellow arrow).
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c)

c) PHE165 and TRP58 involved in pi-pi stacking interactions with the aromatic rings of RS1-208b. PHE163 and
TRP58 provide hydrogen bonds with the oxygen atoms of the functional groups on the aromatics rings. HIS164
forms a hydrogen bond with the ketone moiety.

Table 11. Docking Scores of RS1-208b and b-AP15 to UCHL5
Ligand
RS1-208b
b-AP15

Docking Score
-4.54
-3.30
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a)

Figure 12. In Silico Docking of RS1-208b onto USP14
a) RS1-208b is capable of binding onto the groove of USP14 that surrounds the catalytic cysteine at position 114.
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b)

b) Lysine residues at positions 448 and 453 are involved in hydrogen bonding with the oxygen atom of the methoxy
functional group on the aromatic ring and the nitrogen atom from the 4-piperidinone, respectively, stabilizing the
molecule on the groove near Cys114.

Table 12. Docking Scores of RS1-208b and b-AP15 to USP14
Ligand
RS1-208b
b-AP15

Docking Score
-4.26
-5.12
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7. Confirming Up-Regulation of Transcripts Using RT-qPCR
7.1 PMAIP1 Up-Regulation
The confirmation of up-regulation of transcripts induced in HL-60 cells by RS1-208b,
detected through AmpliSeq analysis, was performed using real-time reverse transcriptase
polymerase chain reaction (RT-qPCR). Due to Noxa’s crucial role in apoptosis following ER
stress81,84–86,88–90, confirmation of PMAIP1 up-regulation was prioritized.
HL-60 cells (400,000 cells/2mLs/well in a 24-well plate) treated with either 2µM RS1208b or PEG-400 (0.3% v/v) for 6 hours. Three separate experiments (each with 3 biological
replicates per treatment) were conducted. The cell line and time point were selected for direct
comparison to AmpliSeq data. Again, PEG-400 was selected as the vehicle control to minimize
the effect contributed to the vehicle (see Figure 17.). Following treatment, cells were collected
into micro-centrifuge tubes and centrifuged for 5 minutes at 1400rcf. Cells were then washed
with ice cold PBS and centrifuged (5 minutes at 1400rcf), twice. PBS was aspirated and the dry
pellet stored at -80ºC overnight. The following morning, RNA was extracted using Qiagen’s
RNeasy Mini Kit (74104), following the protocol provided, along with the optional Qiashredder
(79654) and DNAse II digestion steps, to maximize RNA extraction and minimize DNA
contamination. RNA quantification and purity assessment was performed using the NanoDrop.
The results for individual replicates are summarized below (Table 13). A260:A280 ratios above 2.0
and A260:A230 ratios above 1.7 were taken to indicate successful RNA extraction and purity of
RNA.

Table 13. RNA Extraction for RT-qPCR Shows High Purity
Sample ID
Sample Volume
ng/µL 260/280 260/230
PEG-400-1-1
30µL
126.94
2.09
1.77
PEG-400-1-2
30µL
111.37
2.13
1.87
66

PEG-400-1-3
PEG-400-2-1
PEG-400-2-2
PEG-400-2-3
PEG-400-3-1
PEG-400-3-2
PEG-400-3-3
RS1-208b-1-1
RS1-208b-1-2
RS1-208b-1-3
RS1-208b-2-1
RS1-208b-2-2
RS1-208b-2-3
RS1-208b-3-1
RS1-208b-3-2
RS1-208b-3-3

30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL
30µL

103.92
82.86
57.47
63.01
90.87
65.18
77.43
67.62
71.93
118.72
77.06
92.96
65.86
85.90
92.39
93.94

2.12
2.07
2.00
2.06
2.07
2.04
2.00
2.10
2.12
2.08
2.03
2.07
2.06
2.07
2.05
2.07

1.81
2.02
1.84
2.04
2.22
1.94
1.87
2.14
1.79
1.76
1.92
2.29
2.09
2.29
2.18
2.20

The synthesis of cDNA was performed using Qiagen’s RT2 HT First Strand Kit (330411)
immediately following RNA extraction and purification. The genomic DNA elimination step,
along with the DNAse II digestions performed during the RNA extraction and purification,
reduces the possibility of DNA contamination. Total RNA used for each reaction was 500ng,
with the volume adjusted to 9µL per reaction using nuclease free water. Reverse transcription
was performed using Bio-Rad iCycler with the following program: 15 minutes at 42ºC, 5
minutes at 95ºC, hold at 4ºC.
Primers for the RT-qPCR verification of transcript up-regulation of select genes in
response to treatment with RS1-208b were purchased from Bioneer. β-Actin (ACTB) was used
as a control gene. The sequences of the primers used are found in Table 14.

Gene
ACTB85
PMAIP185

Table 14. Primer Sequences Used in RT-qPCR Experiments
Forward Primer
Reverse Primer
5'-GGCACCCAGCACAATGAAG-3'
5'-GCCGATCCACACGGAGTACT-3'
5'-GCTGGAAGTCGAGTGTGCTA-3' 5'-CCTGAGCAGAAGAGTTTGGA-3'
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The PCR reaction was performed in 0.2mL thin walled tubes. The reaction consisted of
12.5µL of 2x SYBR Green I, 3.5µL of each forward and reverse primer, 4µL of cDNA, and
1.5µL of nuclease free water. Total PCR reaction volume was 25µL. Final primer concentration
was 700nM. Annealing temperature was determined for each set of primers using New England
Biolab’s Tm calculator (http://tmcalculator.neb.com/#!/). Primer sequence specificity was
independently verified by Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/).
The real-time PCR protocols used are summarized in Table 15. Melt curves were included to
confirm target sequence amplification specificity (data not shown).

Initial Denaturation
PCR

Table 15. Real-Time PCR Protocol
Cycle(s) Step
ACTB
1
95ºC:10(min)
40 Denaturation
95ºC:10(sec)
Annealing (Tm)
Extension

Final Extension
Melt Curve
Hold

1
80
1

54ºC:10(sec)
72ºC:4(sec)
72ºC:10(min)
Start 54ºC (+0.5ºC)
10ºC:∞

PMAIP1
95ºC:10(min)
95ºC:10(sec)
53ºC:10(sec)
72ºC:4(sec)
72ºC:10(min)
Start 53ºC (+0.5ºC)
10ºC:∞

Analysis of up-regulation (fold-count) is summarized and compared to AmpliSeq in
Table 16. Data represented below is the average (± standard deviation) up-regulation from three
separate experiments (biological replicates = 3). ACTB was used as the housekeeping gene85.
Fold-count up-regulation is normalized to PEG-400 (0.3% v/v) treated cells.

Table 16. Comparison of Up-Regulation Fold-Count (FC) between AmpliSeq and RTqPCR
Gene
AmpliSeq (FC) RT-qPCR (FC)
PMAIP1
20.66
14.91 ± 5.46
68

Though fold-count differed slightly between the two methods used to detect upregulation of PMAIP1 transcripts, RT-qPCR confirms up-regulation of PMAIP1 in response to
treatment of HL-60 cells with RS1-208b.
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8. Evaluating Proteotoxic Stress and Noxa Translation Induced by RS1-208b
8.1 Accumulation of Poly-Ubiquitinated Proteins in Response to RS1-208b
Like the proteasome inhibitor Bortezomib, b-AP15 leads to the rapid accumulation of
poly-ubiquitinated proteins112. However, b-AP15 does not inhibit either the caspase-like, trypsinlike, or chymotrypsin-like activity of the proteasome112, suggesting b-AP15, and RS1-208b,
could be a useful chemotherapeutic option for patients who initially respond well to proteasome
inhibitors, such as Bortezomib, but develop resistance.
Enrichment analysis of AmpliSeq data (later confirmed through RT-qPCR) along with
the in vitro assessment of apoptosis, which confirmed the intrinsic pathway induced by the
compound, provided a signaling pathway that began with the ER response to stress and resulted
in apoptosis. In silico docking of RS1-208b onto cysteine deubiquitinases UCHL5 and USP14
provided a molecular target of the compound that is upstream of ER stress. To confirm that
treatment with RS1-208b lead to proteotoxic stress, which initiates the molecular signaling
cascade we have observed, we performed immunoblot analysis to detect the accumulation of
poly-ubiquitinated proteins112–114 (proteotoxic stress) and link deubiquitinase inhibition to the
PERK-mediated unfolded protein response.
Cells were incubated at a concentration of 200,000 cells/mL with either 2µM MG132,
2µM RS1-208b, or 0.3% v/v of PEG-400 and collected at 1 hour and 5 hours. Cells were then
centrifuged at 1400rcf for 5 minutes and subsequently washed in PBS. Cells were then pelleted
by centrifugation at 1400rcf for 5 minutes and the PBS removed by vacuum. Laemmli buffer
(2x) was added to each pellet (150µL) in a micro-centrifuge tube and boiled at 100ºC for 10
minutes. The samples were then re-suspended in the Laemmli buffer by pipette and centrifuged
at 1400rcf for 5 minutes. The supernatant was collected into a new micro-centrifuge tube and the
samples were quantified using NanoDrop. Untreated cells were used as a negative control.
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Accumulation of poly-ubiquitinated proteins following 1 hour of treatment was resolved
using an 8% SDS-PAGE gel, run at 100 volts for 1 hour, and transferred to a PVDF membrane at
100 volts for 1 hour. The membrane was blocked overnight at 4ºC using 5% non-fat milk in
TBS. The PVDF membrane was then probed with primary antibody against glyceraldehydy 3phsphate dehydrogenase (GAPDH), used as a loading control, in 5% BSA-TBST(0.1%) for one
hour at room temperature at a dilution of 1:1000. The secondary antibody (Goat anti-mouse) was
incubated for 1 hour in TBS at a dilution of 1:2000, and the film developed. Primary antibody
against ubiquitin was incubated at room temperature at a dilution of 1:1000. Goat anti-mouse
was then incubated for 1 hour in TBS at a dilution of 1:2000, and the film developed.
The Un-SCAN It software was used to perform the densitometry analysis of the Western
blots. Pixel counts for high molecular weight (> 250kDa) and ubiquitination of proteins (50kDa250kDa) were normalized to the loading control, GAPDH, for every treatment. All treatments
were then normalized to the untreated, negative control. The results are found in Figure 13.
The rapid accumulation of poly-ubiquitinated proteins has been observed as early as 1
hour following treatment with DUBs inhibitor b-AP15112. Treatment with RS1-208b showed a
drastic change in the accumulation of high molecular weight (> 250kDa) poly-ubiquitinated
proteins compared to MG-132 (see Figure 13a). The data presented below confirm RS1-208b’s
ability to inhibit, albeit, indirectly, the 26S proteasome.
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a)

High molecular weight poly-Ub-proteins
6

Fold-change

5
4
3
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1
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RS1-208b

Figure 13. Accumulation of Poly-Ubiquitinated Proteins after 1 Hour of Treatment with
RS1-208b
a) RS1-208b induces the rapid accumulation of poly-ubiquitinated proteins of high molecular weight (> 250kDa).
This effect is greater than that observed with MG-132.

b)

Ub-proteins

GAPDH
b) Western blot showing GAPDH and poly-ubiquitinated proteins. High molecular weight poly-ubiquitinated
proteins were taken to be proteins weighing above 250kDa.
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c)

Poly-Ub-proteins
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Fold-change
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c) Fold-change of poly-Ub-proteins in response to DUB inhibition by RS1-208b after 1 hour. The observed
accumulation of total poly-ubiquitinated proteins was markedly higher than treatment with MG-132. The vehicle
control treatment was similar to the untreated controls.

8.2 Noxa Expression in Response to RS1-208b
Noxa selectively binds to and inhibits MCL-184, initiating the mitochondrial dependent
intrinsic apoptotic pathway. Noxa has been shown to be a crucial factor in apoptotic death induced
by proteotoxic stress82,88,89.
Expression of Noxa as a result of ER stressors MG-132 and Bortezomib has been detected
as early as 4 hours after treatment88. Due to the mitochondrial depolarization we observed in RS1208b treated cells at 5 hours, we figured Noxa expression should be induced by this time point if
we are observing Noxa dependent death. Furthermore, the 5 hour time point falls within the
experimental observations of Noxa expression peaking between 4 and 8 hours after treatment87.
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a)
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b)

GAPDH
Noxa
Figure 14. Noxa Up-Regulation after 5 Hours of Treatment with RS1-208b
a) Fold-change in Noxa expression following 5 hours of treatment. Noxa up-regulation of protein expression is
comparable to the positive control, MG-132. Expression of Noxa was normalized to GAPDH, and all treatments
were normalized to the untreated control. b) Western blot for loading control GAPDH and Noxa.

Cells were incubated at a concentration of 200,000 cells/mL and treated with either 2µM
MG132, 2µM RS1-208b, or 0.3% v/v of PEG-400 and collected at 1 hour and 5 hours. Cells
were then centrifuged at 1400rcf for 5 minutes and subsequently washed in PBS. Cells were then
pelleted by centrifugation at 1400rcf for 5 minutes and the PBS removed by vacuum. Laemmli
buffer (2x) was added to each pellet (150µL) in a micro-centrifuge tube and boiled at 100ºC for
10 minutes. The samples were then re-suspended in the Laemmli buffer by pipette and
centrifuged at 1400rcf for 5 minutes. The supernatant was collected into a new micro-centrifuge
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tube and the samples were quantified using NanoDrop. Untreated cells were used as a negative
control.
Noxa expression was assessed at 5 hours after treatment. Noxa has been reported to peak
between 4-8 hours after proteotoxic stress. Due to the mitochondrial depolarization observed at 5
hours after treatment, we hypothesized that by this time point, Noxa expression will be prevalent
and that the subsequent inhibition on MCL1 allows for oligomerization of Bak.
Noxa expression was resolved using a 10% SDS-PAGE gel run at 100 volts for 1 hour,
and transferred to a PVDF membrane at 100 volts for 1 hour. The membrane was blocked
overnight at 4ºC using 5% non-fat milk in TBS. The PVDF membrane was then probed with
primary antibody against Noxa in 5% BSA-TBST (0.1% Tween-20) for one hour at room
temperature at a dilution of 1:1000. The secondary antibody (Goat anti-mouse) was incubated for
1 hour in TBST (0.1% Tween-20) at a dilution of 1:2000, and the film developed. GAPDH
(loading control) in 5% BSA-TBST(0.1%) for one hour at room temperature at a dilution of
1:1000. The secondary antibody (Goat anti-mouse) was incubated for 1 hour in TBST (0.1%
Tween-20) at a dilution of 1:2000, and the film developed. Primary antibody against ubiquitin
was incubated at room temperature at a dilution of 1:1000. Goat anti-mouse was then incubated
for 1 hour in TBST (0.1% Tween-20) at a dilution of 1:2000, and the film developed.
The Un-SCAN It software was used to perform the densitometry analysis of the Western
blots. Pixel counts for Noxa were normalized to the loading control, GAPDH, for every
treatment. All treatments were then normalized to the untreated, negative control. The results are
found in Figure 14.
Noxa is constitutively expressed in hematological cancer cell lines119. Despite this, there
was an appreciable increase in Noxa expression following treatment with either MG-132 or RS1-
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208b. Moreover, densitometry analysis confirmed the up-regulation in expression in these
treatments compared to the negative control. The fold-change calculated for MG-132 was 2.78
and for RS1-208b was 2.75, showing comparable Noxa expression between our compound and
the positive control.
The expression of Noxa we observed at 5 hours could be what leads to the depolarization
of the mitochondrial membrane induced by RS1-208b following DUB inhibition, accumulation
of poly-ubiquitinated proteins, preferential translation of ATF4, and transcription of ATF3 and
PMAIP1.
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9. Evaluating RS1-208b in Vivo
9.1 Severe Compromised Immuno-Deficient (SCID) Mice and Cell Line Selection for in
Vivo Studies
C.B-17/lcrHsd-Prkdcscid , SCID mice, were selected for in vivo modeling due to their lack
of functional T and B cells, which allow for xenotransplantation120. One female SCID mouse was
injected subcutaneously (5e6 cells suspended in 200µL of serum-free RPMI) on the right flank
with RAMOS and on the left flank with BJAB in order to test the tumorigenicity and growth rate
of the cell lines. There is no evidence suggesting the cell lines are capable of metastasizing when
injected subcutaneously121, therefore we attributed tumor growth as successful engraftment of the
cell line, depending on which side of the mouse it grew.
The cytotoxicity assays performed identified Burkitt’s Lymphoma as particularly
susceptible to RS1-208b treatment. Furthermore, measuring tumor progression in subcutaneous
models is more economically feasible, and less time consuming, than tracking disease
progression of disseminated models and Burkitt’s Lymphoma is a hematological malignancy that
generally manifests itself in patients as a solid tumor. Both Burkitt’s lymphoma cell lines
(RAMOS and BJAB) have been reported to engraft subcutaneously in immune-deficient mice122,
though there are also studies which contradict the potential engraftment of BJAB123. The tumor
growth rates appear to be similar from the palpable detection of a tumor to the time it takes to
reach ~1500mm3 124.
In our hands, the BJAB model failed to engraft subcutaneously by day 28, consistent with
several studies123, whereas the Ramos model grew to ~1300mm3 in that amount of time, and was
palpable 20 days after inoculation of cells. We therefore selected the RAMOS cell line for
xenotransplantation and in vivo modeling and evaluation of RS1-208b.
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Table 17. Tumor Size after 28 Days
Cell Line Tumor Volume (mm3)
Ramos
1345.65
BJAB
0.00
Tumor Volume = L x 2W x π/6

9.2 Pilot Experiment-RAMOS Subcutaneous Model
Tumor cells grown in mice and serially re-passaged typically have better engraftment
rates and the time from inoculation to measurable tumor is usually shortened125. Therefore, when
conducting the pilot experiment to test the therapeutic potential of RS1-208b, the cells harvested
from the previously mentioned experiment were selected for subcutaneous inoculation of 6 SCID
mice (3 males and 3 females). However, we observed a markedly slower time to detection of
palpable tumor (33 days compared to 20 days) and the time to ~1300mm3 was 39 days
(compared to 28 days), though the sample size does not allow for proper conclusions to be made.
Despite this, the growth rate from when the tumors were first palpable to when they reached
~1300mm3 in vehicle control mice was not drastically different to the previous experiment (5.5
days compared to 8 days). The engraftment rate for this pilot experiment was 66.67% (4/6; 2
males and 2 females).
Mice with palpable tumors were randomized on day 33 into vehicle (DMSO) control and
treatment (RS1-208b 50mg/kg) groups, each containing 1 male and 1 female. We opted for
intratumoral (IT) delivery to localize the biodistribution126 of the compound and, theoretically,
maximize the effect exerted. Vehicle control mice received 200µL of 10%v/v DMSO and the
RS1-208b treated mice received 50 mg/kg in 200µL of 10%v/v DMSO intratumorally, a
concentration that had previously been deemed safe (causing no discernable systemic toxicity) in
an escalating dose pilot experiment using a syngeneic subcutaneous model of breast cancer. The
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mice were treated 3 times a week after being weighed, examined visually for signs of systemic
toxicity, and having their tumors measured.

Ramos Subcutaneous (Pilot Experiment)
1200

Tumor Volume (mm3)

1000
800
RS1-208b (F)
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Days After Beginning Treatment

12

Figure 15. Pilot Experiment of Subcutaneous Model of RAMOS
The end-point for this experiment was >1200mm3 or 12 days. RS1-208b doubled the number of survival days after
initiation of treatment of compared to vehicle control mice. Vehicle control mice survived an average of 5.5 days
after treatment initiation, whereas RS1-208b treated mice survived for 11.5 days. Sample size too small to determine
statistical significance.

In the pilot experiment, we observed a delay in tumor growth rates in mice treated with
RS1-208b, with one tumor remaining below 200mm3 for the duration of the pilot experiment.
The slower tumor growth rate allowed for longer survival (time to end point) compared to
vehicle control mice, though no statistical significance can be determined given the small sample
size.

9.3 Development of Intraperitoneal Model of RAMOS
Three SCID mice (2 females, 1 male) were injected intraperitoneally (IP) with 5e6 cells
of the Ramos cell line suspended in 200µL of serum-free RPMI. The mice were weighed 3 times
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a week and were visually inspected for intraperitoneal fluid or mass, indicative of successful
engraftment. All SCID mice (3/3) developed intraperitoneal tumors accompanied by a small
volume of ascites fluid formation by day 56 and were euthanized due to compromised
movement.
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Figure 16. Weight Trends of Mice Injected Intraperitoneally with RAMOS
Weights remained steady for 24 days. Mice began gaining weight at a faster rate after day 36, which correlated with
IP tumor growth. Ramos-F1: female mouse 1, Ramos-F2: female mouse 2, Ramos-M1: male mouse 1.

The successful intraperitoneal engraftment rate of RAMOS provided us with yet another
in vivo model of the disease on which we could test the efficacy of RS1-208b. However,
detection of ascites fluid and tumor growth was not visually apparent until day about day 50,
providing only a small window for treatment, by which point the cancer burden on the mouse
could be too great to overcome. We therefore analyzed the weight trends to identify the point in
which the tumors and fluid could have begun to develop, which could be a proper point to begin.
After day 36, the mice began gaining weight at an increased rate, which we attributed to IP
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tumor growth and ascites formation, suggesting that successful engraftment might have been
achieved before this time point.

9.4 PEG-400 Selection for the Vehicle
Upon necropsis of pilot experiment mice, tumors treated with RS1-208b showed
precipitated compound, indicating the formulation was coming out of solution in vivo. Despite
this, in the RAMOS subcutaneous pilot experiment, an effect was observed in the treatment mice
compared to vehicle controls and we attributed this effect to the compound.
To avoid using a higher percentage of DMSO and risking systemic toxicity due to the
vehicle, polyethylene glycol 400 (PEG-400) was looked into as a more suitable vehicle for RS1208b. PEG-400 has been used to dissolve compounds with poor solubility127. Furthermore, PEGs
have been evaluated and found to be safe vehicles for drug administration and it is only at
concentrations higher than are generally used in common practice that they exhibit systemic
toxicity128. However, there are concerns when using PEG-400 intravenously or intraperitoneally
due to its potential to induce hemolysis or reduce plasma volume, but not osmolality, at high
doses (3.5g/kg-8g/kg), though the LD50 isn’t observed until the concentration reaches 9.2g/kg127.
For our modelling purposes, we decided to err on the side of caution and limit our use of PEG400 to concentrations well below the LD50 reported and the concentrations where reduction of
plasma volume begins to be a concern (9.2g/kg and 3.5g/kg, respectively).
PEG-400 is a viscous substance and we had trouble loading a syringe for injection.
Therefore, we tested dilutions of PEG-400 in PBS (another inert vehicle) at 100% v/v PEG-400,
50% v/v PEG-400, 30% v/v PEG-400, and 10% v/v PEG-400 in order to determine at which
concentration by volume it was feasible to load a syringe using a 28 gauge needle, selected to
minimize discomfort to the mice at time of administration. Solutions containing <50% v/v PEG81

400 were able to be loaded into a syringe fitted with a 28 gauge needle with relative ease. We
decided on using 30% v/v PEG-400 to help the compound remain in solution and minimize the
amount of vehicle used.
Moreover, we diluted the compound using this solution prior to testing in vivo to ensure
the compound remained in solution. We found that at a concentration of 5mg/kg the compound
remained in solution but at higher concentrations, observable precipitation occurred even after
vigorous vortexing. We next tested the 30% v/v PEG-400 formulation of RS1-208b for
cytotoxicity compared to DMSO using the PI exclusion assay on a small panel of hematological
cancer cell lines at 1% concentration of final volume. Overall, we observed a greater cytotoxic
effect when using DMSO (p < 0.05) as the vehicle control, indicating that perhaps PEG-400 was
a more suitable vehicle for studying the cytotoxic effects of RS1-208b by minimizing the effect
of the vehicle (see Figure 17).
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Figure 17. Assessment of Cell Death Induced by Vehicles PEG-400 and DMSO
The cytotoxic effects of the two vehicles were assessed in four different hematological cancer cell lines. PEG-400
exhibited less cytotoxicity than DMSO after 24 hour treatment (p < 0.05).

9.5 RAMOS Subcutaneous Model
Curcumin and EF-24 have been tested on mice bearing subcutaneous tumors39, with
minimum effective dose calculated to be 20mg/kg33,129. However, we were unable to dissolve
RS1-208b in the 30% v/v PEG-400 formulation at a concentration higher than 5mg/kg.
Encouragingly, SCID mice bearing FaDu tumor xenografts treated with b-AP15 (5mg/kg)
through subcutaneous injection showed a significant delay in tumor growth when compared to
vehicle112. This suggested that even at these lower concentrations, given RS1-208b’s structural
similarity to b-AP15 and its improved cytotoxicity profile compared to both EF-24 and
curcumin, we would be able to achieve tumor growth delay.
RAMOS cells obtained from a previous subcutaneous engraftment were injected into
SCID mice (n = 19). The mice were randomized into an RS1-208b treatment group (n = 10) and
a vehicle control group (n = 9) when the tumors reached ~200mm3. After the tumors reached this
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size, they were dosed 3 times a week with 5mg/kg112 RS1-208b or vehicle and tumor
measurements (Tumor volume = L x 2W x π/6) and mouse weights were taken 3 times a week.
The end point selected was tumor volume >1200mm3. Compound stability was assessed via
mass spectrometry before the initiation of in vivo modelling (data not shown).

RamosSQ-Tumor Graph

Tumor Volume (mm3)

1400
1200
1000
800
Vehicle Control

600

RS1-208b (5mg/kg)

N.S.

400
200
0
1

3

5
8
10 12 15 17
Days After Treatment Initiation

19

Figure 18. RS1-208b Delays Tumor Growth in RAMOS Subcutaneous Model
RS1-208b delays the tumor growth for 12 days. Tumor growth progression (± SEM) is shown above. No statistical
significance was observed between RS1-208b treated and vehicle treated tumors at each measuring point, though
there was an apparent delay in tumor growth, with RS1-208b treated tumors measuring, roughly, between ½ and 2/3
of the vehicle treated for 12 days.

Table 18. Ratio of Tumor Growth Comparing RS1-208b Treated Mice with Vehicle
Treated Mice in Subcutaneous Model of RAMOS
Days After Treatment
Initiation
3
5
8
10
12
15

RS1-208b/Control
0.53
0.49
0.54
0.65
0.67
0.99
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Though not statistically significant, there was an appreciable delay in RAMOS tumor
growth between RS1-208b treated and vehicle treated mice that lasted through the first 12 days
of treatment. The ratio of RS1-208b to vehicle treated tumor size at each measuring point was
between ½ and 2/3 for the first 12 days.
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Figure 19. RS1-208b Extends Event-Free Survival Time in RAMOS Subcutaneous Model
RS1-208b extends event-free survival time in RAMOS subcutaneous model (p < 0.05). Median event-free survival
for vehicle treated mice was 11 days compared to 14.5 days for RS1-208b treated mice.

The Kaplan-Meier survival curve (Figure 19) shows treatment with RS1-208b on the
RAMOS subcutaneous model significantly (p <0.05) increased event-free survival, as measured
by the Chi-Square test. Though not statistically significant when compared to vehicle control
tumor size, the delay in tumor growth observed in RS1-208b treated mice lead to a significant
increase in the number of mice surviving past the expected number of days established by the
vehicle control.
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9.6 RAMOS Intraperitoneal Model
Ramos cells obtained from previously successful intraperitoneal engraftment were
injected intraperitoneally into the lower right quadrant of SCID mice (n=9). Mice were
randomized into RS1-208b treatment and vehicle control groups 24 days after the injection, at
which point, treatment began: 10µM RS1-208b (n = 5) or vehicle (n = 4), delivered 5 times a
week intraperitoneally. Mice were visually inspected daily for behavioral and body condition
score changes. Furthermore, the mice were weighed 3 times a week to track tumor engraftment.
The end point selected was 30% weight gain (compared to initial average weight), before tumor
burden compromised quality of life, or appreciable drop in body condition score.
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Figure 20. RS1-208b Extends Event-Free Survival Time in the RAMOS Intraperitoneal
Model
RS1-208b significantly (p < 0.005) increases event-free survival in the RAMOS intraperitoneal model. Median
survival for vehicle treated mice was 33 days compared to 46 days median survival for RS1-208b treated mice.
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The median survival time was increased in the RS1-208b treated mice by about 50%
compared to vehicle control (see Figure 20). The event-free survival time difference between
RS1-208b treatment and vehicle control group was very significant (p < 0.005).
Despite being about 1/10 of the dose used in the subcutaneous model of RAMOS, the
effect in the intraperitoneal model was much more pronounced. Method of delivery would be a
potential explanation for the increased efficacy in the intraperitoneal model. However, despite
delivering RS1-208b intraperitoneally, there were solid tumors in the peritoneal cavity upon
necropsis, suggesting the delivery could also be considered intratumoral. We hypothesize that the
increase in efficacy is due largely to the increased frequency of RS1-208b doses. The rapid
systemic clearance of curcumin19 could also affect its analogs, suggesting more frequent and
smaller doses could be more effective in treating cancers in vivo.
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10. Conclusion
10.1 Discussion
RS1-208b inhibits the deubiquitinating activity of cysteine DUBs that associate with the
19S regulatory particle of the 26S proteasome. In silico docking of RS1-208b onto UCHL5
indicates the aromatic rings and the functional groups that surround it, along with the ketone
moiety of the compound, orient RS1-208b so that the unsaturated β-carbonyl comes in close
proximity to the catalytically crucial cysteine residue, and, presumably, initiate a Michael
reaction with the thiol group38. However, the effect on USP14 is likely due to the compound
competing with ubiquitin chains for the pocket surrounding the catalytic Cys114 since the
orientation we observed through in silico docking experiments suggest the unsaturated βcarbonyl does not come in close proximity to the cysteine’s thiol group. The inhibition of
deubiquitinating activity results in the accumulation of poly-ubiquitinated proteins within 1 hour
of treatment which induces proteotoxic stress and initiates a cellular signaling cascade that
culminates in apoptosis.
Though the exact mechanism by which proteasome inhibition leads to the PERKmediated unfolded protein response is not clearly understood62,65, data analysis of our AmpliSeq
results indicated that the PERK-mediated UPR is activated in HL-60 cells following 6 hours of
treatment with RS1-208b. Activated PERK is a kinase that phosphorylates eIF2α, an important
subunit of the 43S translation initiation complex whose phosphorylation inhibits the rapid
exchange of GDP-GTP, essentially halting global translation. Under these conditions, transcripts
with uORFs are preferentially translated. ATF4 is one such transcript with two uORFs whose
preferential translation during ER stress conditions is important for the transcription of PMAIP1.
Noxa, the translated product of PMAIP1, crucial for the intrinsic apoptotic pathway82, selectively
binds the anti-apoptotic protein of the Bcl-2 family MCL-1, releasing MCL-1’s inhibitory effect
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of Bak82,84. This allows for Bak oligomerization, which leads to the depolarization of the
mitochondrial outer membrane and the release of protons, cytochrome c, and calcium ions into
the cytosol. Cytochrome c, along with Apaf-1, combine to form the apoptosome, cleaving and
activating caspase-9, which in turn activates the effector caspase, caspase-3, resulting in cell
death. Furthermore, cytochrome c acts as a ligand for the inositol triphosphate receptor on the
ER membrane, leading to more calcium ion release into the cytosol. Calcium dependent
scramblases externalize phosphatidylserine to signal that the cell is undergoing apoptosis and
allow for recognition by macrophages.
In vivo assessment of the effects of the compound indicate RS1-208b is very well
tolerated at concentrations up to 50mg/kg and that it has a positive effect in extending event-free
survival time in two different xenograft models, even at low concentrations.
These results suggest treatment with RS1-208b could be a legitimate alternative
chemotherapeutic option, especially for high-risk leukemia cases in the U.S. Hispanic
population, whose disproportional mortality rates due to childhood cancers highlight the need for
improved chemotherapy options. Moreover, RS1-208b could be used in cases where patients
initially respond favorably to proteasome inhibitors but develop resistance by offering an
alternative which results in the same pathway of cell death but targets deubiquitinases.
In addition, the low systemic toxicity we observed, along with its inhibition of
inflammatory cytokines IL-636 and TNFα emphasizes RS1-208b’s ability to be used in
combination therapy, though preliminary in vitro data hasn’t shown a synergistic effect with
established chemotherapy compounds (data not shown).
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10.2 Future directions
Proteomics is a fascinating and quickly expanding field that promises to provide
researchers with data about the proteome (the entire proteins present in the cell)130,131. Much like
with the RNA-sequencing analysis, the changes in the proteome as the cell responds to treatment
with RS1-208b will allow us to quickly identify the molecular pathway and the proteins involved
in the execution of apoptosis. Despite the usefulness of transcriptome analysis, up-regulation in
transcription does not necessarily result in an up-regulation in translation131, making
corroboration of results with proteomics important in identifying the major molecular players.
We have recently submitted RS1-208b treated and vehicle treated samples for proteomics
analysis at the Biomolecule Analysis Core Facility (BACF) of the Border Biomedical Research
Center (BBRC) at UTEP. We hope to be able to identify overexpressed (compared to vehicle
control) proteins in the PERK-mediated UPR that had transcripts up-regulated in RS1-208b
treated cells, thus, strengthening the argument for RS1-208b inducing apoptosis through
proteotoxic stress. Moreover, proteomics analysis of Noxa expression should corroborate our
Western blot data showing an increase in expression following treatment with RS1-208b.
Noxa’s central role in cell death due to RS1-208b could be further explored to confirm
the compound induces Noxa-dependent apoptosis. Evaluation of other proteotoxic stressors
indicate transient silencing of Noxa expression using siRNAs attenuates apoptotic cell death89.
Lastly, our Annexin V data implicated a non-apoptotic pathway of cell death that the
ELISA assay for TNFα and the cytokine production inhibition29 of RS1-208b suggest is not
necrosis. Autophagy has garnered much interest lately and some of the up-regulated genes we
observed in response to RS1-208b have been implicated in this form of cell death66,85,103. BAG3
(Bcl2 associated athanogene) has received attention as a gene that is important for the transition
to autophagy and it is believed this transition occurs as a result of proteasome inhibition132–134.
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Though the mechanism is still being investigated, it seems that switch to autophagy results from
the cell’s attempts to degrade proteins that are normally degraded by the 26S proteasome and
reduce proteotoxic stress132,133. By re-analyzing our transcriptome data and using the data we will
obtain from the proteomics study, we might be able to contribute valuable insights into this
switch to autophagy and help elucidate the molecular mechanism underlying the switch.
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Glossary
*
**
ACTB
AIDS
Akt
ALL
AML
ATF3
ATF4
ATF6
ATP
BACF
BAG3
BBRC
BCL2
BH3
BiP
BL
BSA
bZIP
cMAP
Contraction
CPRIT
DAPI
DMSO
DOD
DUB
E1
E2
E3
eIF2α
ELISA
ER
ERAD
FITC
GADD34
GAPDH
GDP
GO
GTP
HMOX1

p < 0.05
p < 0.005
Beta-actin
Acquired Immune Deficiency Syndrome
Protein Kinase B
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Activating Transcription Factor 3
Activating Transcription Factor 4
Activating Transcription Factor 6
Adenosine Triphosphate
Biomolecule Analysis Core Facility
BCL2 Associated Athanogene 3
Border Biomedical Research Center
B-cell Lymphoma 2
Bcl2 Homology Domain 3
Binding Immunoglobulin Protein
Burkitt's Lymphoma
Bovine Serum Albumin
Basic Leucine Zipper Domain
Connectivity Map
Definition
Cancer Prevention Research Institute of Texas
4’,6-diamidino-2-phenylindole, dihydrochloride
Dimethyl Sulfoxide
Department of Defense
Deubiquitinase
Ubiquitin Activating Enzyme
Ubiquitin Conjugating Enzyme
Ubiquitin Ligase
Eukariotic Initiation Factor 2α
Enzyme-Linked Immunosorbent Assay
Endoplasmic Reticulum
ER Associated Degradation
Fluorescein isothiocyanate
Growth Arrest and DNA Damage-Inducible Protein 34
Glyceraldehyde 3-phosphate dehydrogenase
Guanosine Diphosphate
Gene Ontology
Guanosine Triphosphate
Heme Oxygenase 1
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IC50
IL-6
IP
IRE1α
IT
JAK/STAT
JC-1
MAPK
MCL-1

Inhibitory Concentration
Interleukin-6
Intraperitoneal
Inositol Requiring Enzyme 1α
Intratumoral
Janus Kinase/Signal Transducers and Activators of Transcription
5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide
Mitogen-Activated Protein Kinase
Myeloid Cell Leukemia 1
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2HMTS
tetrazolium, inner salt
MYC
c-MYC
NADH
Nicotinamide adenine dinucleotide
NADPH
Nicotinamide adenine dinucleotide phosphate
NCI
National Cancer Institute
NF-kB
Nuclear Factor kB
NGS
Next Generation Sequencing
NHL
Non-Hodgkin's Lymphoma
ORF
Open Reading Frame
PAGE
Polyacrylamide gel electrophoresis
PBMC
Peripheral Blood Mononuclear Cells
PBS
Phosphate Buffered Saline
PEG-400
Polyethylene Glycol 400
PERK
PKR-like ER Kinase
PMAIP1
Phorbol-12-Myristate-13-Acetate Induced Protein 1
PMS
Phenazine Methosulfate
POH1
RPN11, a Ubiquitin C-Terminal Hydrolase
proteostasis Protein Homeostasis
PS
Phosphatidylserine
PVDF
Polyvinylidene Fluoride
RT-qPCR
Real-Time Quantitative Reverse Transcription
SCID
Severe Compromised Immuno-Deficient
SDS
sodium dodecyl sulfate
SI
Selectivity Index
SQ
Subcutaneous
TBS
Tris Buffered Saline
TBST
Tris Buffered Saline (0.1% Tween-20)
TNFα
Tumor Necrosis Factor-α
UCHL5
Ubiquitin C-Terminal Hydrolase L5
uORF
Upstream Open Reading Frame
UPR
Unfolded Protein Response
UPS
Ubiquitin-Proteasome System
USP14
Ubiquitin Specific Peptidase 14
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UTEP
XBP1

The University of Texas at El Paso
X-Box Protein 1
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